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CHAPTER I 
INTRODUCTION 
Dimethyl sulfoxide (DMSO) has gained increasing notoriety as a quick 
acting remedy for sprains, strains, contusions, and other injury related 
disorders (Clark and Hager, 1981; Reed, 1981). This publicity has in-
creased the unsupervised use of DMSO by laymen and athletes who hope to 
find a miracle cure for their injuries. Research on the effectiveness of 
dimethyl sulfoxide has had varying results. 
Reduction of edema is a primary objective in treating athletic in-
juries, especially ankle sprains. Edema increases healing time by irri-
tating the tissues of the injured area and by congesting normal blood 
flow. Any modality that can be found to speed the reduction of edema 
will help decrease healing time and be very beneficial to an injured 
athlete. A review of literature has indicated that the use of DMSO may 
have an effect on the reduction of edema. Brown (1971) demonstrated 
that, in the treatment of bursitis, 80% DMSO was effective in reducing 
inflammation while 10% DMSO was not. Oerud (1982} cited dimethyl sulfox-
ide as being a hydroxyl radical scavenger which causes DMSO to move fluid 
from the edemic area into the blood. DMSO also has been shown to perform 
as a fast acting carrier of cortisone into the stratum corneum. This 
penetration has been demonstrated to take place in less than five minutes 
(Oerud, 1982). Maiback and Feldman (1967) demonstrated a threefold in-
crease in skin penetration when cortisone was dissolved in DMSO and ap-
plied to the skin. 
1 
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In the past, injections of corticosteroids around injured tendons 
and ligaments have been used to tre~t inflammation in these structures. 
Follow-up studies have indicated that if the corticosteroid was inadver-
tently injected into a tendon or 1 igament, it had a tendency to weaken 
the connective tissue (Ryan, 1978). Since DMSO may carry a corticoster-
oid into the tissue, this may be a noninvasive way to introduce a corti-
costeroid into the injured area. 
Statement of Problem 
Dimethyl sulfoxide has been shown to reduce edema and to possess 
carrying and penetrating properties. Maibach and Feldman {1967) demon-
strated that DMSO carried substances into the stratum corneum. The 
problem this study addressed was whether the DMSO could carry a corti-
costeroid {fluocinonide) into the underlying tissues and be more effec-
tive in reducing edema in sprained ankles than could DMSO alone. 
Importance of Study 
This study provides valuable information to sports medicine prac-
titioners concerning the effectiveness of dimethyl sulfoxide used in 
combination with a corticosteroid on sprained ankles. Previous studies 
have shown DMSO to have varying degrees of success. However, these prior 
studies used primary observation rather than direct measurement to obtain 
their data. As a result of this research, physicians will have the in-
formation necessary to make educated decisions on the use of dimethyl 
sulfoxide in combination with a corticosteroid. 
Hypothesis 
The following hypothesis was tested at the .05 level of 
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significance: 
There is no significant difference in the effect of dimethyl sulfox-
ide and dimethyl sulfoxide with .05% fluocinonide on edema in sprained 
ankles over the testing period. 
Limitations 
The research was limited by the following factors: 
1. The physical effects of DMSO may be different in individuals 
with varying chemical makeups and skin types. 
2. The measurement of the foot/ankle may have been affected by the 
length of time the subjects were on their feet during the day or by the 
amount of water retention at the time of measurement. 
3. Edema may have been affected by the subjects practicing or not 
practicing football during the testing period. 
Del imitations 
The research was delimited by the following factor: 
The subjects were male, collegiate football players at Oklahoma 
State University who were between the ages of 18 and 22, and who had sus-
tained sprained ankles. 
Definition of Terms 
Dimethyl Sulfoxide (DMSO). A solvent derived from woody plants 
which is used medically for the treatment of sprains, strains, contu-
sions, and many other physical disorders. (A description of 90% DMSO is 
listed in Appendix A.) The chemical formula for DMSO is: CH3-S-CH3. 
/f 
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Fluocinonide .05%. Topical corticosteroid used for the relief of 
inflammatory and pruritic conditions that have a vasoconstrictive action. 
(A complete description of fluocinonide is listed in Appendix B.) The 
chemical formula for fluocinonide is CH2 OCCH3 
I 
C=O 
Volumeter. A commercially available device that measures the volume 
of feet and ankles by submerging the area to be measured in water and 
weighing the amount of water displaced (Archimedes' principle). 
Obturator. A commercially available device used in conjunction with 
a volumeter to reduce the surface area of the water., 
Archimedes' Principle. This principle states that a body immersed 
in a fluid is buoyed up by a force equal to the weight of the displaced 
fluid. (The amount of fluid displaced by an object is equal to the vol-
ume of the object.) 
Edema (Swelling). A local or generalized condition in which the 
body tissues contain an excessive amount of tissue fluid. 
High Frequency Galvanic Current. A form of electrotherapy using 
approximately a 300 kHz frequency to treat inflammatory disorders, circu-
latory problems, and post-traumatic states following athletic injuries 
(sprains, contusions, dislocations, and hematomas). 
Whirlpool. A form of hydrotherapy using jets of water to give the 
injured area an underwater massage. 
CHAPTER II 
REVIEW OF LITERATURE 
Dimethyl sulfoxide (DMSO) is a highly controversial, experimental 
drug which has been approved by the Federal Drug Administration (FDA) for 
human use in limited clinical situations. This review of literature 
discusses the history of DMSO, its chemical properties, clinical effec-
tiveness, side effects, and the previous clinical investigations pertain-
ing to this study. 
Dimethyl sulfoxide is a simple, naturally occurring organic com-
pound. It is an inexpensive, colorless solvent which is derived from 
1 igni n as an industrial byproduct. Lignin is the organic cement that 
combines with cellulose to form the major portion of woody plants. DMSO 
is synthesized by oxidizing dimethyl sulfoxide with nitrogen oxide. It 
is used as an industrial solvent in the manufacture of rayon and orlon 
synthetic fibers, as an antifreeze or hydraulic fluid mixed with water, 
as.a paint or varnish remover, as a carrier solvent for insecticides, as 
a topical dressing for trauma in horses, and as a treatment for incurable 
bladder disorders in humans. 
Dimethyl sulfoxide was first synthesized by Saytzeff (cited in 
Oerud, 1982) in 1866. It was not patented, however, until the 1940's, 
when Crown Zellerback used it as an industrial solvent (Albrechsten and 
Harvey, 1982). DMSO was introduced to medicine by Jacob (cited in Oerud, 
1982) in 1963 for use in the reduction of arthritic swelling. Jacob 
. promoted DMSO as having certain beneficial pharmacological properties for 
patients. 
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The following are Jacob•s (cited in Harter, 1983) assumptions: 
1. DMSO penetrated the intact skin rapidly and carried a num-
ber of chemicals with it; thus, some injections would not 
be necessary. 
2. Various inflammatory diseases could be controlled because 
DMSO inhibited a number of prostaglandins. 
3. DMso•s logal analgesic properties could reduce pain from 
swelling. 
4. Science could harness DMso•s ability to dissolve amyloid 
and collagen compounds. 
5. DMSO reduced intracranial pressure in head injuries, thus 
reducing mortality from head injuries (p. 1). 
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At the present time, the FDA has approved DMSO for human studies. 
During the period of 1963 to 1965, over 100,000 persons received the drug 
in experimental studies. In 1965, the FDA rescinded permission for DMSO 
to be used in human clinical studies. This decision came following the 
development of lenticular myopia in small, nonprimate animals treated 
with large doses of DMSO in several experimental studies. Further clini-
cal data failed to show the same change in human lens refraction. Harter 
( 1983) stated: 
Our toxicologists have reviewed studies on DMSO in seven spe-
cies, all of which, after some dose for some duration, show 
incompletely reversible changes in the lens. It would be a 
biological quirk for human lenses not to behave similarly 
(p. 5). 
Rubin (1983, p. 8) found that DMSO did not accumulate in the eye lens. 
In the DMSO-affected lens, there was a 11 ••• decreased concentration of 
urea, uric acid, glutalhioxe and amino acids, with an increase in albumi-
noids. The lens change is not caused by either hydration or dehydration 
nor does DMSO bind to lens protein ... 
The FDA approved DMSO again in 1966 for clinical studies concerning 
such untreatable diseases as scleroderma (thickening of skin and some 
internal organs) and persistent herpes zoster (shingles). The approval 
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for clinical use of DMSO in less serious conditions (such as bursitis and 
sprains) came in 1968. Fifty percent DMSO gained FDA approval in 1973 
for incurable bladder conditions such as interstitial cystitis. The only 
product currently approved by the FDA for use in humans is a 50% DMSO 
solution marketed as 11 Rimso-50 11 by the Research Industries Corporation 
( 11 Topical DMSO as therapy in patients, 11 1980) of Salt Lake City, Utah. 
In 1980, the FDA lifted restrictions on human studies, but still 
considered DMSO as an investigational new drug. The FDA gave approval 
for the Research Industries Corporation to study extensively the effect 
of DMSO on athletic injuries. Mr. Marv Robertson, the athletic trainer 
at Brigham Young University, has been working with research specializing 
in sprains and strains. 
After almost three years of work, I have concluded that DMSO is 
effective on soft-tissue injuries •••• It•s erratic, but it 
has no side effects except an occasional rash and bad breath. 
It reduces recovery time by 50%, on the average. It•s amazing 
stuff. I think it should be 1 egal ized as a controlled sub-
stance. If aspirin were submitted to the FDA today for ap-
proval, it would take 10 years for approval and it would be a 
prescription drug. And, unlike aspirin, DMSO hasn•t been 
proven responsible for one death yet (cited in Reed, 1981, 
p. 75). 
However, DMSO has not been approved for general use by the FDA. This 
would include approval for use on soft tissue injuries. 
The Journal of the American Medical Association ( 11 Dimethyl sulfox-
ide: Controversy and current status, 11 1982) stated that DMSO is reported 
to be clinically effective in the following: (1) acute musculoskeletal 
injuries and inflammations; (2) diseases of connective tissues {rheuma-
toid arthritis, cutaneous manifestations of scleroderma, ankylosing 
spondylitis and gout); (3) burns; (4) post-operative pain; (5) viral, 
fungal, bacterial, and parasitic skin infections; (6) wound healing; (7) 
interstitial cystitis; and {8) mental conditions. 
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Dimethyl sulfoxide is a controversial drug which is sometimes i 1-
legally used. It has been increasingly hailed by a large number of pro-
fessional and amateur athletes who look at it as a panacea for all types 
of ills from sprains to torn muscles. Even members of the medical pro-
fession hold differing opinions about DMSO. According to Dr. Frank Jobe 
(cited in Reed, 1981), orthopaedist for the Los Angeles Dodgers (a pro-
fessional baseball club) and a founder of the National Athletic Health 
Institute (NAHI), 11 It•s quite spectacular on soft-tissue injuries like 
sprains, contusions, bursitis, tendonitis. It could revolutionize sports 
medicine 11 (p. 72). Dr. Robert Kerlan (cited in Reed, 1981), sports or-
thopaedist and a founder of NAHI, said: 11 DMSO has some medical benefits, 
but curing routine sports injuries isn•t one of them. It•s almost use-
less for athletes 11 (p. 72). Athletic trainer Dick D1 0livia (cited in 
Reed, 1981, p. 75) said: 11 When a trainer uses DMSO, he uses ice, ultra-
sound, acupuncture, anything--all at the same time. He doesn•t have time 
to sort out his treatments. 11 D10livia continued by explaining that no 
one knows how much of a patient•s rehabilitation is locked up in his 
head. Dr. Stan James (cited in Reed, 1981) and Oregon orthopaedist, has 
a more reasonable view of DMSO: 
DMSO is no miracle. . . • It•s effective, yes. But when you 
withhold something from the public, whether it•s laetrile, 
marijuana, liquor or Playboy, an artificial madness is created. 
DMSO is not dangerous. Legalize it, and it will take it•s 
place in the pharmacology of sports medicine. People won•t 
believe it, but miracles are few and far between. Penicillin 
was the last one, and DMSO is not penicillin (p. 75). 
Pierre Pilote, a professional hockey player with the Chicago Black Hawks, 
might disagree with Dr. James• opinion that DMSO is not a miracle drug 
(Reed, 1981). In 1965, Pilote treated his dislocated shoulder with DMSO 
and started skating immediately. Sandy Koufax, a professional baseball 
player, used DMSO on a nagging elbow and was able to pitch brilliantly in 
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the 1965 World Series {Reed, 1981). Daryle Lamonica of the Oakland Raid-
ers (a professional football team) used DMSO in 1968 on his jammed thumb 
and the swelling decreased in 15 minutes {Reed, 1981). However, DMSO did 
not work on his torn ligament. Lamonica stated that a number of profes-
sional football players used DMSO and 11 ••• the only side effect we ever 
noticed was body odor and incredibly bad breath 11 {Reed, 1981, p. 74). 
Because of DMso•s popularity in the sports arena, especially professional 
sports, several states have legalized its manufacture, prescription, and 
use under specified conditions. Florida now warns physicians and li-
censed health care practitioners against prescribing veterinary or indus-
trial grade DMSO for their patients. There could be harmful contaminants 
in the industrial solution which may prove hazardous to the individual 
using OMSO. The veterinary product is usually a 90% solution which pro-
duces greater cutaneous toxicity. 
The chemical properties of OMSO are the following: chemical empiri-
cal formul a--C2H605, structura 1 formul a--CH3-S-CH3, specific gravity--
1.1014, molecular weight--78.15, melting point--18.4°C, boiling point--
1890C, flashpoint--95°C (Jacob and Wood, 1971). 
DMSO is available in either gel or solution form. The highly polar 
dimethyl sulfoxide is miscible in water, ethanel, acetone, ether, ben-
zene, and chloroform in the same manner in which alcohol goes into solu-
tion with water. It is exothermic, giving up 60 calories per gram when 
it is mixed with water. DMSO binds readily with moisture in the air 
(hygroscopic); however, when it is mixed 50-50 with water, it does not 
freeze, even at -270°C. For this reason, it can be used as an antifreeze 
and as a cryogenics solution. 
Dimethyl sulfoxide penetrates the skin rapidly. It crosses most 
body membranes without harming them. When radioactively labeled DMSO has 
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been rubbed on human skin, it has been detected in the blood in less than 
five minutes (Oerud, 1982). The peak level of concentration in the blood 
occurs between four and six hours. DMSO appears to remain at a constant 
level in the blood for 36 to 72 hours. It does not penetrate the nails 
or the tooth enamel (Maibach and Feldman, 1967). Maibach and Feldman•s 
(1967) study on the percutaneous penetration of hydrocortisone in DMSO in 
humans showed that the maximum excretion occurred within 36 hours. They 
concluded that there was a threefold increase in penetration when corti-
sone was dissolved in DMSO and applied to the skin. When DMSO had a 
tracer added (i.e., methylene blue) but no cortisone, biopsies showed the 
stratum corneum was completely stained. Little or no staining occurred 
below this level (Maiback and Feldman, 1967). 
Stoughton and Fritsch (1964, p. 516) reported that 11 ln the case of 
transient exposure, DMSO was superior to water in promoting penetration 
of hydrocortisone by a factor of about seven. 11 Klingman (1965) demon-
strated that when there were steroids dissolved in solutions of 70% DMSO 
or greater, there was an enhanced skin penetration. Sulzberger (cited in 
McOermot, Murray, and Heggie, 1965) concluded from his experiments that 
since DMSO carries substances rapidly into the horny layer of the skin, 
it must be useful as a therapy vehicle for agents used on inflammatory 
dermatoses and superficial skin infections. DMSO carries hydrocortisone 
into the deeper layers of the skin (stratum corneum), 11 ••• producing a 
reservoir which remains for 16 days and resists depletion by washing the 
skin surface with soap, water and alcohol 11 (Jacob and Wood, 1971, p. 3). 
Serum levels of DMSO are lower after dermal administration than 
after oral administration (Maiback and Feldman, 1967). Dermal absorption 
appears less complete than does gastrointestinal absorption. 
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The distribution of DMSO in the body is widespread. Traces of DMSO 
have been found in all body tissues, since it binds to protein in the 
blood. The highest concentration of DMSO appears to be found in the 
stomach, spleen, lungs, and skin. The lowest concentration of DMSO has 
been found in the cartilage, joint fluid, bone, eye lens, and adrenal 
glands (Oerud, 1982). 
Dimethyl sulfoxide is metabolized by the body into OMS, DMS02, and 
DMSO. OMS is excreted by the lungs. One-and-one-half to three percent 
of the total dosage given is excreted during the first 24 hours. DMS02 
and DMSO are given off by the kidneys, which is the main elimination 
route in humans (Oerud, 1982). Fifteen percent of the total dosage is 
excreted during the first 24 hours, and 50% during a 10-day period. Only 
a small amount of DMSO is excreted in the stool. The only site of DMSO 
accumulation is the skin (John and Laudahn, 1967). 
DMSO is an anti-inflammatory agent. This is due to the fact that 
dimethyl sulfoxide is a hydroxyl radical scavenger, which is a response 
initiated by white blood cells (Oerud, 1982). There is a decreased anti-
body response and decreased antibody reproduction. The thirst DMSO pro-
duces is its key to relieving edema and pain. When DMSO moves fluid into 
the blood, it makes the body•s work of healing quicker, easier, and less 
painful by relieving pressure and swelling (Reed, 1981). DMSO does not 
heal tissues by itself. 
Weismann, Sessa, and Bevans {1967) documented that lysosomes can be 
stablized by cortisone. When cortisone was dissolved in DMSO, the amount 
of cortisone necessary to stabilize the lysosomes was reduced from tens 
to thousands. They suggested the possibility that DMSO rendered the 
steroids more available to target tissues. 
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Percy and Carson {1981), in a study of 80 patients using 70% DMSO, 
showed that DMSO was not effective in tennis elbow and rotator cuff ten-
donitis. The double-blind study of 70% DMSO and 5% DMSO assessed pain 
tenderness, but did not measure swelling, include X-rays of the injured 
areas, or characterize the injury or its duration. The application of 
DMSO was unsupervised. Twenty-two percent of the ori gina 1 subjects 
dropped out of the study. 
Brown {1971) showed that in the treatment of bursitis, 80% DMSO was 
effective in reducing inflammation, while 10% DMSO was only fair to poor 
in reducing inflammation. The result obtained from standard therapy was 
comparable to the result obtained with 80% DMSO. 
McDermott, Murray, and Heggie ( 1965) applied 6% DMSO to patients • 
skin. They found that it reduced the nerve conduction velocity by 40% 
for the first two weeks. This activity diminished and disappeared soon 
after the two-week period ended. 
When the skin was swabbed once or twice a day with DMSO, a mild site 
erythematous scaling dermatitis appeared at the site. This rash re-
gressed as the treatment progressed. 11 Skin erythema, edema, and pruritus 
are frequent occurrences in humans when concentrations of DMSO greater 
than 70% are used, but such side reactions also occur at concentrations 
of 10% 11 (Rubin, 1983, p. 7). A study using 80% DMSO prescribed for the 
patient at a ratio of one gram per kilogram per day was conducted on male 
prison volunteers. There were 78 subjects and 33 controls. No signifi-
cant laboratory systemic side effects were noted, and all subjects had 
norma 1 eye 1 ens ex ami nations. There were, however, sever a 1 minor side 
effects. These included the following: sedation {52%), headache {42%), 
nausea (32%), and skin irritation and increased eosinophile count (18%) 
{Paul, 1967). The volunteer subjects also complained of generalized 
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dermatitis, diarrhea, burning irritation, and allergic reactions. Mild 
ointments help skin scaling and irritation, but the irritation decreases 
with continued usage. 
The eye lens refraction change in most species of animals appears to 
be do se-re 1 a ted. Eye 1 ens refraction has not been reported in human 
beings. When OMSO was given orally to dogs, rabbits, and pigs, it re-
sulted in 11 ••• alterations of the refractive index of the lens with a 
progressive myopia. Lenses from treated anima 1 s do not become opaque 11 
(Jacob and Wood, 1971, p. 2). Not all species appeared to be affected 
equally. Rabbits were the most sensitive animals, while rhesus monkeys 
were the least sensitive to lens change brought about by OMSO. Kutschera 
(cited in John and Laudahn, 1967) treated 84 patients for an average of 
2-1/2 months with average doses of 18.4 milliliters of 90% OMSO. No 
toxicity to the eyes was noted. 
Scherbel, McCormack, and Pappa's (1965) observations on 47 patients 
who had scleroderma, and who were given several ophthalmologic examina-
tions, showed no toxicity after taking OMSO. The highest dosage was 30 
milliliters of 90% DMSO; the longest treatment period was 2.5 years. 
Gordon and Kleberger (1968) stated: 
If any single fact has emerged from animal and human studies 
with DMSO to date, it is that the lens toxicity findings orig-
inally reported in dogs and later confirmed in certain other 
species have no equivalent or counterpart in human therapy 
utilizing DMSO in generally accepted regimens (p. 423). 
There appears to be a marked increase in urine production when DMSO 
is used. The probable cause of the increase is an osmotic duresis, along 
with increased amounts of both sodium and potassium excretions (Oerud, 
1982). DMSO, when applied as a pretreatment, has the tendency to make 
some resistant bacteria sensitive to antibiotics. This activity is help-
ful in treating skin infections. 
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Albrechtsen and Harvey (1982, p. 179) found that 11 The topical appli-
cation of dimethyl sulfoxide was associated with periods of decreased 
mean separation forces in tendons. 11 They strongly suggested that vigor-
ous exercise and muscular activity be avoided during DMSO therapy, due to 
the tendons' increased susceptibility to injury. Sports Medicine Digest 
( 11 DMSO weakens tendons [in mice]," 1983) concurred with this suggestion. 
Brown (1967), in a clinically controlled, double-blind study of 75 
patients with acute sprains and tendonitis, used 10% and 80% DMSO gel. 
He proved that the 80% DMSO gave greater relief from tenderness and pain 
for longer periods of time and allowed greater range of motion than did 
the 10% solution of DMSO. The results of the 80% DMSO were comparable to 
results expected from normal treatment. 
Myrer, Hickmann, and Francis (1986) investigated the use of topi-
cally applied DMSO to traumatized muscles of 80 rats. The rats were 
traumatized, treated, and sacrificed to discover the number of histologic 
healing cells. The rats were assigned to either a healing or inflamma-
tion group, and then were further divided into a control group (100% 
distilled water) and an experimental group (70% DMSO and 30% distilled 
water). During each treatment, the rats received one milliliter of 
either DMSO or water, while the inflammation group received an additional 
15 treatments during a five-day period. Myrer, Hickmann, and Francis 
(1986) found that 
Significantly fewer healing cells were present in the experi-
mental group than in the control group during the period in-
flammation was examined and no significant difference existed 
between the experimental and control groups during the period 
healing was examined (p. 165). 
The drug DMSO has great potential in the treatment of various 
traumas. The most noticeable side effects are bad breath (amicably re-
ferred to as 11 death breath") and a distinguishable body odor. The 
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intensity of the odor varies from individual to individual. 11 Death 
breath 11 appears within five minutes after application of DMSO. A 10% 
aqueous solution of DMSO, although ineffective, produces the revealing 
11 0yster 11 breath. In the lungs, the body releases dimethyl sulfoxide in 
the gas exchange, causing the odor. Only withdrawing the drug will alle-
viate breath odor. Because of this distinguishing odor, taste, and bad 
breath, there is some difficulty in setting up a double-blind study. 
The University of Oregon Medical School has monitored patients who 
have been using dimethyl sulfoxide for as long as two years with hema-
logic and chemical tests (Jacob and Wood, 1971). No significant abnor-
malities were found. Treating patients topically with DMSO produced 
potent histamine liberation at the application site. 
The Drug Education Committee of the National Athletic Trainers Asso-
ciation has recognized 99 injuries/conditions that they considered worthy 
of further investigation of DMSO treatment (Weismann, Sessa, and Bevans, 
1967). {A list of these injuries/conditions may be found in Appendix C). 
There is an extensive amount of literature to warrant the investiga-
tive uses of DMSO as a therapeutic modality. It has not been proven to 
be a single, miracle cure for athletic injuries. DMSO is best used as an 
adjunct to conventional therapy, not as a replacement. It requires con-
tinuous study by qualified sports medicine professionals in order to 
determine optimum dosage and application techniques. 
Summary 
Dimethyl sulfoxide was released in 1980 by the FDA as an 
investigational new drug. Research Industries Corporation of Salt Lake 
City, Utah, markets a 50% DMSO solution called 11 Rimso-50, 11 the only prod-
uct currently approved for human use by the FDA. 
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DMSO has proven to be effective in the treatment of acute musculos-
keletal injuries, connective tissue disease, burns, post-operative pain, 
skin infections, wound healing, interstitial cystitis, and various mental 
conditions. A large number of amateur and professional athletes view 
DMSO as a panacea for the treatment of numerous types of injuries. How-
ever, experimental and clinical studies over the last two decades have 
not proven conclusively that DMSO is more effective in the treatment of 
athletic injuries than are conventional methods. 
Maibach and Feldman•s (1967) study concluded that there was a three-
fold increase in skin penetration when cortisone was dissolved in DMSO 
and applied. Stoughton and Fritsch (1964) showed that DMSO was superior 
to water in promoting penetration of hydrocortisone by a factor of seven. 
Weismann, Sessa, and Bevans {1967) documented that cortisone can 
stabilize lysosomes. When cortisone was dissolved in DMSO, the amount of 
corti sane necessary to stabilize the lysosomes was reduced from tens to 
thousands. 
Brown (1971) showed that 80% DMSO was effective in reducing bursitis 
inflaRiTiation; however, the conclusions were comparable to results ob-
tained solely with standard treatment. Albrechtsen and Harvey (1982) 
demonstrated that topically app 1 i ed DMSO produced periods of decreased 
tendon mean separation. Thus, A 1 brechtsen and Harvey suggested that 
vigorous muscular activity be curtailed during DMSO treatment. Sports 
Medicine Digest ( 11 DMSO weakens tendons [in mice], 11 1983) concurred with 
this study. 
Myrer, Hickmann, and Francis (1986) experimented with applying 80% 
DMSO, 30% DMSO, and 100% distilled water on traumatized rat muscles. 
After sacrificing the rats, they discovered that fewer healing cells were 
present in the DMSO group than were present in the distilled water group. 
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Also, there was no significant difference between the two groups during 
the healing period. 
The literature has shown that DMSO is not a miracle cure for ath-
letic injuries to be used in place of conventional therapeutic modali-
ties; rather, it should be used as part of a total rehabilitative program 
after research determines the optimum DMSO dosage and application 
techniques. 
CHAPTER III 
METHODS AND PROCEDURES 
This research was designed to test the hypothesis that, over time, 
there was no significant difference in the effect of dimethyl sulfoxide 
and dimethyl sulfoxide with .05% fluocinonide on edema in sprained an-
kles. The edema volume in the injured ankle and the volume of the unin-
jured ankle was measured using the basics of the Archimedes• Principle. 
The post-injury measurements were subtracted from the pre-injury measure-
ment to determine the volume difference. The volume difference repre-
sented the volume of edema changes in the injured ankle and the volume 
changes in the uninjured ankle. 
Selection of Subjects 
The population for this study consisted of collegiate football play-
ers at Oklahoma State University who were between the ages of 18 and 22. 
The subjects were selected from a pool of 123 members of the Fall, 1987, 
Oklahoma State University football team. The 14 participants were ran-
domly selected by the athletes• acquisition of sprained ankles and their 
willingness to participate in the research. All members of the football 
team were pre-measured with the prospect of possible ankle sprains, 
thereby becoming candidates for participation in the study. 
All subjects treated with dimethyl sulfoxide or dimethyl sulfoxide 
with fluocinonide were required to sign an informed consent form, demon-
strating their willingness to participate in the research {Appendix D). 
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In the state of Oklahoma, dimethyl sulfoxide is recognized as a prescrip-
tion drug. The Oklahoma State Board of Health requires an alternative 
mode of treatment release to be signed by the patient and the prescribing 
physician (Appendix E). A 11 participants were asked to read both re-
leases and were invited to ask any questions before they were included in 
the study. The participants were under close scrutiny by the supervising 
physician and sports medicine personnel. In the event that any abnormal-
ities had arisen, the subjects had available prompt and appropriate medi-
cal attention. 
Instrumentation 
The devices used to measure prospective subjects and participants 
were two conmercially available foot and ankle volumeters with obtura-
tors. Figure 1 shows the measuring instruments used to collect the data. 
Figure 1. Photograph of Measuring Instruments 
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The weight of the water displaced by the subjects'foot/ankle/lower 
leg was the measurement used to determine the size of each of the sub-
jects' ankles pre- and post-injury. By utilizing the Archimedes 
Principle, the edema changes as demonstrated by the amount of water dis-
placed could be accurately measured. The water was weighed on a commer-
cially available Detecto scale used in blood banks and laboratories to 
make measurements in one gram increments. The volumeters and obturators 
were labeled "right" and "left," so that the same devices were used to 
measure the same ankle each time. 
A protocol was determined by using the manufacturer's guidelines, in 
order to insure consistency of procedure for each measurement. The fol-
lowing procedures were precisely adhered to each time measurements were 
taken. The directions given to the subjects were the same for the ini-
tial measurement and for all additional measurements: 
1. Before daily testing, the accuracy of the Detecto digital scale 
with the Ohaus exact weights was checked. The 10-gram weight was weighed 
first and then the next higher weight was added, up to the total of 
12,100 grams. It was ascertained that the scale read the exact weight 
each time a weight was added. The two receivers (mixing pitchers) were 
weighed to assure a weight of 165 grams each. The scale zeroed out with 
one of the receivers on the scale. The receiver was removed and checked 
to see if the scale read 165 grams. 
2. Before each measurement was taken, the position of the chair and 
the volumeters were checked. Caution was taken to insure that the chair 
and the volumeters were on the appropriate line marked on the floor. The 
volumeters (right and left) were situated in the correct position in 
front of the chair, with the overflow spouts pointing away from the sub-
ject. The receivers were placed under the overflow spouts. 
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3. The right and left obturators were filled with water from the 
holding tank (20 gallon plastic trash container) to within 1/2 11 of the 
top. The obturators were placed into their corresponding volumeters with 
water from the holding tank until water came out of the overflow spout. 
The water sat for three minutes; a stop watch was used. Although the 
water generally stopped coming out of the overflow in about two minutes, 
the full three minutes were used to confirm that the water had leveled 
off. The receivers were emptied, dried with a towel, and then were re-
weighed to ascertain that they were zeroed out on the scales. 
4. The subject sat on the chair with his back against the chair 
back and his arms on the arm rests. The right obturator was lifted and 
the subject immersed his right foot slowly into the volumeter. The lower 
leg was perpendicular to the floor, with the heel and ball of the foot 
sitting on the bottom of the volumeter. The back of the heel was touch-
ing the back of the volumeter. The obturator was replaced into the top 
of the volumeter. The procedure was then repeated with the left foot. 
The subject was asked to relax; the only pressure on the feet was the 
weight of the subjects• legs. After the subject was correctly positioned 
and relaxed, he was instructed to remain relatively motionless for three 
minutes (a stop watch was used). 
5. After two minutes, the water had stopped coming out of the over-
flow spout. However, the full three minutes was used to insure that the 
water had leveled off. The. right receiver was removed and placed on the 
Detecto seale, the weight was recorded on the record sheet, and this 
process was repeated with the left receiver. 
6. The subject waited to remove his feet until both receivers were 
weighed, in order to avoid the splashing of water into either receiver. 
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After the weighing was completed, the obturators were removed and the 
subject withdrew his feet from the volumeters. 
7. Step #3 was repeated so that the volumeters were ready to mea-
sure the next subject. 
8. At the end of the day, the volumeters, obturators, and receivers 
were cleaned and dried. The holding tank was filled with fresh water so 
that the water would be room temperature for the following day's testing. 
A reliability test of the volumeters and obturators was completed 
before the actual i nvesti gati on measurements began. A uniformity trial 
was used to check reliability. This trial was analyzed using an analysis 
of variance. Twelve football players were selected at random and both 
ankles were measured once a day for five days (Monday through Friday) at 
approximately the same time each day. This produced a 12 x 2 x 5 fac-
torial experiment. The testing procedures used were identical to those 
used in the present study. An analysis of variance was used to determine 
reliability. Results of the reliability test are shown in Table VI {Ap-
pendix H). The results of the reliability test indicated a difference 
(P < .01) among ankle volumes. This was expected, due to the different 
heights and weights of the football players tested. There were no other 
significant differences (P = .05) in the changes in ankle volume over the 
five-day testing period. Figure 7 (Appendix H) shows the relationship 
between the left and right ankle over the reliability testing period. 
The dimethyl sulfoxide and fluocinonide used in this research were 
purchased from a pharmacy located in Stillwater, Oklahoma. The solution 
of 90 milliliters of 70% DMSO and 90 milliliters of 70% OMSO with a .01% 
concentration of fluocinonide was calculated and prepared by a registered 
pharmacist using the formula stated in Appendix F. The OMSO solutions 
were mixed in individual, 90 milliliter, airtight, light resistant, amber 
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glass, graduate bottles with child-resistant caps. The bottles were 
grouped in blocks of two--one bottle for each of the two treatments--
because only a small number of subjects were expected to participate. 
This insured treatment groups of the same size. The bottles were labeled 
with the pharmacy label and the identifying bottle code numbers (i.e., 
BLOCK 1, BOTTLE 1). As each bottle was assigned to a subject, the phar-
macist was notified as to which bottle and block was being used on each 
particular subject. The pharmacist then wrote the subject•s name on the 
corresponding prescription. The pharmacist was the only person routinely 
notified during the study as to which solution was used on any subject. 
The supervising physician could obtain this information at any time in 
the event of an adverse reaction to the treatments. 
Data Collection 
Immediately after sustaining an ankle sprain, each candidate re-
ceived the standard treatment consisting of 15 minutes of ice, compres-
sion, and elevation. During this initial treatment, the subject was 
asked to participate in the study. If the subject agreed to take part in 
the research and signed both release forms, his ankles were measured. 
Measurements were then recorded on the ankle injury record sheet (Appen-
dix G). The subject•s skin was washed thoroughly and 30 milliliters of 
one of the two DMSO solutions was applied, using four 3 x 3 gauze pads. 
The DMSO bottles were assigned in the order of the participants entering 
the study. The DMSO was rubbed into the skin and was covered with a 
plastic-backed, cellulose compress material. An elastic wrap was loosely 
applied, and each subject was instructed to leave the wrap and the DMSO 
on for 12 hours. The subject was told to return the following morning 
for another measurement and treatment. 
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The treatment regimen consisted of a cold (65° - 55°} whirlpool for 
15 minutes, 10 minutes of high frequency galvanic current with the ankle 
elevated, and 10 minutes of cold whirlpool three times daily. An elastic 
wrap was reapplied after each treatment. Before football practice, the 
subject•s ankles were measured again. If the subject could practice, the 
ankle was taped; if not, he stayed in the training room and received the 
standard treatment. After practice, both of the subject•s ankles were 
again measured and a second treatment of DMSO was applied to the injured 
ankle. This process continued until three applications of DMSO were 
given and three consecutive days of measurements were taken. Additional 
measurements were taken on the fourth and seventh days after the injury 
occurred. 
Analysis of Data 
The data were compiled on the 14 subjects and analyzed using an 
analysis of variance. 
Corporation Software. 
The analysis was done on a computer using the SAS 
This was a 7 x 2 x 2 x 12 split-split plot experi-
mental design (7 blocks, 2 treatments, 2 ankles, 12 measurements on each 
ankle). The mean volumes that were used for the computations were the 
pre-injury measurements minus the post-injury measurements (volume 
difference). 
Summary 
To compare the two dimethyl sulfoxide treatments as to their effec-
tiveness, commercially available foot and ankle volumeters were used to 
pre- and post-test ankle volume to measure changes in the amount of edema 
in the injured ankle. By accurately measuring the volume of the ankles 
before an injury occurred, the investigator established a pre-test 
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measurement for the injured ankle. For the purposes of this study, the 
effectiveness of the two DMSO treatments was based on the amount of edema 
reduced over the one-week testing period, as measured by changes in the 
volume of the ankles. 
CHAPTER IV 
RESULTS 
The purpose of this study was to test the hypothesis that, over the 
168-hour testing period, there would be no difference in the effect of 
dimethyl sulfoxide and dimethyl sulfoxide with .05% fluocinonide on the 
reduction of edema in sprained ankles. All Oklahoma State University 
football players• ankles were premeasured using corrmercially available 
volumeters. Those players who acquired sprained ankles participated in 
the study. All post-injury measurements were subtracted from the pre-
injury measurement to derive a volume difference value. From the 123 
football players pretested, 14 subsequently became subjects in the study. 
Seven subjects received 70% DMSO and seven subjects received 70% DMSO 
with fluocinonide. A total of 12 measurements were taken after the in-
jury on both ankles of the subjects over a seven-day peri ad. The data 
campi led on the 14 subjects over the treatment and measurement period 
appear in Table VII (Appendix H), and a summary of the time, treatment, 
and ankle means is shown in Table VIII (Appendix H). The results of the 
analysis of variance on the sprained ankles are shown in Table I. 
In comparing the results of the effect of dimethyl sulfoxide and 
dimethyl sulfoxide with fluocinonide it was found that, over time, the 
linear slopes were negative and identical (P < .05). This is demon-
strated in Figure 2. The quadratic curvature of the DMSO curve was dif-
ferent from the DMSO with fluocinonide curve (P < .01). The cubic (curve 
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downward and back upward) over time were identical (P = .05). The aver-
age cubic curvature was significant (P < .01). The uninjured ankle was 
measured throughout the study and the resulting data is shown in Table 
II. 
TABLE I 
VOLUMETER RELIABILITY TEST DATA 
SOURCE OF SUM SQUARES M.S. F 
TOTAL 167 692,508.99 
Blk 6 159,381.04 26,563.51 0.74 NS 
Trt <Chk vs Trt) 1 100,891.01 100,891.01 2.82 NS 
Blk*Trt <Error Al 6 215,039.87 35,839.98 
Time 11 50,856.64 
Time Linear <T 1) 1 8,424.34 8,424.34 6.39 * Time Quad <T2> 1 7,548.59 7,548.59 5.72 * Time Cubic: <T3> 1 24,234.32 24,234.32 18.37 ** Time Residual 8 10,649.39 1,331.17 1.01 NS Blk*Time <Error 8) 66 87,062.82 1,319.13 
Trt*Time 11 21,028.78 
Trt*'T1 1 400.70 400.70 0.45 NS Trt*T2 1 18,336.29 18,336.29 20.78 ** Trt*T3 1 65.52 65.52 0.07 NS Trt*Time Residual 8 1,726.26 215.78 0.24 NS Blk*Trt*Time <Error C> 66 58,248.85 882.56 
** Signific:ant at a =.01 
* Signif"ic:ant at a =.05 
NS Not Signific:ant at a = .05 
Figure 3 shows the mean volume difference for the DMSO uninjured 
ankle and the DMSO with fluocinonide uninjured ankle. The linear slopes 
were equal and were not significantly different from zero (P > .05). The 
quadratic curvatures were not the same (P < .01), and the cubic curva-
tures were not different (P = .05). The average cubic curvature was 
MVOLOIF 
110 
100 
90 
80 
70 
60 
50 
40 
30 
20 
I + 
I 
+ 
I 
c"' /\ I "'c c 
+ 
I 
+ 
I 
+ 
I 
"c-/ \/c~-, 
'-~ ....... 
'~ !  
o--o 
+ ! I I ./ I I ' + I I I I i 
+I / lc / 
+ 
I I 
+ I 
ld 
i 
' 0-
- 0' 
' 
'0--D 
' 
' \ 
' 
' 0-- 0 
I 
\ 
\ 
I 
o-
_o----
c 
-- -o 
--
10 + 
I 
0 + 
-+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+------------------0 12 24 36 ~8 60 72 84 96 108 120 132 144 156 168 
Hours 
-- C = DMSO {Injured) 
-- D = DMSO + Fluocinonide (Injured) 
Figure 2. Comparison of Mean Volume Difference for DMSO Injured 
and DMSO With Fluocinonide Injured Ankles N 
co 
29 
significant (P < .01); both curved downwards and back upwards. The DMSO 
with fluocininode ankle rose slightly higher than did the DMSO curve. 
TABLE II 
ANALYSIS OF VARIANCE FOR VOLUMETER RELIABILITY 
·-·~---
SOURCE DF SUM SQUARES M.S. F 
TOTAL 167 200,707.40 
Blk 6 69,249.24 11,541.54 4.22 NS 
Trt <Chk vs Trt) 1 2.38 2.38 0.00 NS 
Blk*Trt <Error A> 6 16,396.45 2,732.74 
·Time 11 15,394.69 
Time Linear <T1) 1 653.93 653.93 1.17 NS 
Time Quad <T2l 1 1 ,635. 00 1,635.00 2.93 NS 
Time Cubic (T3) 1 6,125.76 6,125.76 10.97 
** Time Residual 8 6,980.01 872.50 1.56 NS 
Blk*Time <Error Bl 66 36,860.48 558.49 
Trt*Time 11 15,202.33 
Tr t*Tl 1 2' 106.50 2,106.50 2.92 NS 
Trt*T2 1 9,185.09 9,185.09 12.74 ** 
Trt*T3 1 120.29 120.29 0. 17 NS 
Trt*Time Residual 8 3,790.45 473.81 0.66 NS 
Blk*Trt*Time <Error Cl 66 47,601.83 721 .24 
** 
Significant at a =.01 
* Signic icant at a =.05 
NS Not Significant at a = .05 
Table III exhibits the combined analysis of variance for the two 
treatments, both ankles and the 12-time measurement periods. Table IV 
shows the mean responses for each ankle and treatment combination. The 
mean volume difference was 62.76 for the injured ankle and 18.94 for the 
uninjured ankle. This difference was significant (P < .01). and was 
expected since the injured ankle would be edemic. The mean volume dif-
ference was 53.16 for the DMSO treatment and 28.54 for the DMSO with 
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TABLE III 
EDEMA RESPONSES TO TWO TREATMENTS ON 
BOTH ANKLES FROM 0 TO 168 HOURS 
SOURCE DF SUM SQUARES M.S. 
TOTAL 335 1,054,479.26 
Blk 6 199,867.49 33,311.25 
Trt CChk VS Trtl 1 50,936.81 50,936.81 
Blk*Trt <Error Al 6 76,482.83 12,747.14 
Leg <Sprain VS Goodl 1 161,262.86 161,262.86 
Blk*Leg <Error Bl 6 28,762.79 28,762.79 
Trt*Leg 1 49,956.57 49,956.57 
Blk*trt*Leg (Error Cl 6 154,953.49 25,825.58 
Time 1 1 53,565.29 
Time Linear <T1) 1 2,192.03 2' 192.03 
Time Quad CT2l 1 8' 104.90 8,104.90 
Time Cubic (T3) 1 27,364.19 27' 364.19 
Time Residual 8 15 '904. 18 1,988.02 
Blk*Time <Error Dl 66 95,411.73 1,445.63 
.Trt*Time 11 33,670.65 
Trt*Tl 1 2,172.34 2,172.34 
Trt*T2 27' 164. 13 27' 164. 13 
Trt*T3 1 4. 13 4.13 
Trt*Time Residual 8 4,330.06 541 .26 
Blk*Trt*Time <Error El 66 77,310.95 1 '171. 38 
Leg* Time 1 1 12,686.03 1,153.28 
Leg*T1 1 6,886~24 6,886.24 
Leg*T2 1 1,078.69 1,078.69 
Leg*T3 1 2,995.89 2,995.89 
leg* Time Residual 8 1,725.22 1,725.22 
Blk*Leg*Time (Error Fl 66 28,511.57 431.99 
Trt*leg*Time 1 1 2,560.46 
Trt*leg*Tl 334.86 334.86 
Trt*Leg*T21 1 857.25 857.25 
Trt*Leg*T3 1 181.69 181.69 
Trt*Leg*Time Residual 8 1,186.66 1' 186.66 
Blk*Trt*Leg*Time <Err Gl 66 28539.73 432.42 
** Significant at a =.01 
* 
Signic:icant at a =.05 
NS Not Significant at a = .05 
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F 
2.61 NS 
4.00 NS 
33.64 ** 
·1. 93 NS 
1. 52 NS 
5.61 * 
18.93 ** 
1.38 NS 
1.85 NS 
23.19 ** 
0.01 NS 
0.46 NS 
15.94 ** 
2.50 NS 
6.93 ** 
3.99 ** 
0.77 NS 
1.98 NS 
0.42 NS 
2.74 ** 
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fluocinonide treatment. Although this difference was 24.62, it was not 
significant (P = .05). 
Ankle 
Uninjured 
Injured 
Mean 
TABLE IV 
EDEMA RESPONSES FOR TREATMENT AND 
ANKLE COMBINATIONS 
DMSO 
19.06 
87.26 
53.16 
Treatment 
DMSO and Fluocinonide 
18.82 
38.25 
28.54 
Mean 
18.94 
62.76 
40.85 
Figure 4 shows the overall average edemic response, beginning at the 
time of injury and continuing for 168 hours. The linear slope of this 
line was not significant (P = .05). The quadratic effect was significant 
(P < .05), as was the cubic effect (P < .01). This was shown by the 
curve, which increased to a maximum of 52.96 at 20 hours, then decreased 
to a low value of 28.32 at 168 hours. The curve tended to flatten after 
84 hours. 
Figure 5 shows the DMSO and DMSO with fluocinonide responses from 
the time of injury to 168 hours. The linear effects were the same for 
both treatments, with no significant slope (P = .05). The quadratic 
curvature for both treatments did not follow the same pattern (p < .01). 
The cubic curvature was essentially identical (P = .05). The two plots 
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showed that the edema for the DMSO curve was higher than the OMSO with 
fluocinonide curve. The DMSO edema curve remained higher from the time 
of injury until approximately 136 hours. The DMSO curve decreased to a 
mean volume difference of 17.21 at 168 hours, while the OMSO with 
fluocinonide curve reached a minimum mean volume difference of 9.71 at 72 
hours, then tended to rise until 168 hours. 
Figure 6 compares the injured ankles to the uninjured ankles without 
regard to the treatments. The linear slope for the injured ankle was 
different from the uninjured ankle (P < .01). The quadratic effects were 
identical and significant at the .01 level. The cubic curvatures were 
different (P < .01). 
Discussion 
Dimethyl sulfoxide and dimethyl sulfoxide with fluocinonide statis-
tically demonstrated that they had significantly similar effects on edema 
during the 168 hour testing period. The difference between the two 
treatments appeared in the quadratic curvature. The DMSO with 
fluocinonide reduced mean volume difference faster during the 24 hour 
through 72 hour measurement period {P < .01). These findings concurred 
with the observation by Maiback and Feldman (1967) on the carrying prop-
erties of DMSO. The corticosteroid fluocinonide appeared to have been 
carried into the tissues and reduced more edema faster than did the DMSO 
alone. Since the DMSO with fluocinonide combination appeared to reduce 
edema faster, it may help the injured ankle heal more quickly. 
A review of the comments on the study's data record sheets indicated 
that the common side effects of DMSO {skin wrinkling and dryness, burn-
ing, rash, itching) were less severe with the DMSO with fluocinonide. 
Bad breath and body odor were reported with both treatments. Apart from 
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the benefits of faster edema reduction, the DMSO with fluocinonide combi-
nation may reduce some of the undesirable side effects. With this infor-
mation, a physician prescribing dimethyl sulfoxide may want to add .05% 
fluocinonide, not only to reduce edema, but also to reduce some of the 
side effects. The cubic curvature seen in the data may be the result of 
a practice effect. All of the subjects had returned to football practice 
the last four days of the measurement period. Therefore, the ankles were 
stressed during practice, causing some of the edema to return. The addi-
tion of another DMSO treatment after the 48-hour post-injury period may 
have helped to reduce this effect. 
The effect on the uninjured ankle appeared to be related to the 
edema in the sprained ankle. It is unknown if this sympathetic effect is 
caused by the DMSO treatments, additional stress put on the uninjured 
ankle from putting less weight on the injured ankle, or a purely physi-
ological response on a paired limb. 
CHAPTER V 
SUMMARY, FINDINGS, CONCLUSIONS, AND 
RECOMMENDATIONS 
Summary 
This research tested the effect of 70% dimethyl sulfoxide and 70% 
dimethyl sulfoxide with .05% fluocinonide on edema in sprained ankles. 
The question this study addressed was whether DMSO with f1uocinonide 
would carry the corticosteroid into underlying edemic tissues and thus 
reduce edema. The subjects were the 1987 Oklahoma State University foot-
ball team members who sustained a sprained ankle. The entire team (123 
members) was premeasured using commercially available volumeters and 
obturators. With the acquisition of a sprained ankle, the athlete was 
included in the study. Fourteen players participated; seven received 70% 
DMSO and seven received 70% DMSO with fluocinonide. Three one milliliter 
applications of one of the two treatments were administered. The first 
application was applied at the time of injury, with the second and third 
treatments being given 24 and 48 hours after the injury. The one milli-
liter DMSO or DMSO with fluocinonide was rubbed on the skin, covered with 
a cellulose compress material, wrapped with an elastic bandage, and left 
on overnight. All of the participants received a standard treatment of 
cold whirlpool and high frequency galvanic current with elevation three 
times a day. The measuring period consisted of seven days, with measure-
ments taken three times a day for the first three days, and once on the 
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fourth and seventh days. This research was a double-blind study in that 
only the pharmacist knew which bottle contained DMSO or DMSO with fluoci-
nonide. The data gathered were analyzed using an analysis of variance. 
It was found that both dimethyl sulfoxide and dimethyl sulfoxide with 
fluocinonide were effective in reducing edema over the testing period. A 
difference in the two treatments• quadratic curves indicated that DMSO 
with fluocinonide was more effective in reducing edema during the 24 to 
72 hour period. Observed side effects of the two treatments differed in 
that the subjects treated with DMSO in combination with fluocinonide had 
less skin wrinkling and dryness, burning, rash, and itching. 
Findings 
On the basis of the results of this study, the following findings 
were drawn: 
1. Dimethyl sulfoxide and dimethyl sulfoxide with fluocinonide 
statistically demonstrated that they have significantly similar effects 
on reduction of edema in sprained ankles over the 168 hour testing 
period. The differences between the DMSO and the DMSO with fluocinonide 
treatments were in the quadratic curvatures. The rate of edema reduction 
was faster for the DMSO with fluocinonide during the 24 hour through 72 
hour period after the injury. 
2. The cubic curvatures observed in the results indicated a recur-
rence of some of the edema during the 1 ast 96 hours of the measuring 
period. 
3. After injury to one of the ankles, the uninjured ankle increased 
in mean volume difference and followed quadratic and cubic curvatures. 
4. Through observation, the side effects (skin wrinkling and dry-
ness, burning, rash, itching) appeared to be less severe with the DMSO 
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and fluocinonide treatment. All of the subjects reported similar prob-
lems with bad breath and body odor a~ ~ result of both treatments. 
Conclusions 
On the basis of the findings of this study, the following conclu-
sions were drawn: 
1. The findings demonstrated that dimethyl sulfoxide with fluoci-
nonide was more effective during the first 24-72 hours at reducing edema 
than was dimethyl sulfoxide alone. For sprained ankles, physicians may 
want to consider using DMSO with fluocinonide as an additional treatment 
to decrease edema and healing time. 
2. Since some edema returned to the sprained ankles during the last 
96 hours, it may be appropriate to use one or two additional treatments 
at 72 and 96 hours after injury. The additional treatments and holding 
the players out of practice may help keep the edema from returning. 
3. It is unknown why the uninjured ankle increased in size during 
the test period. It can be speculated that: (a) the DMSO and DMSO with 
fluocinonide had an effect on the uninjured ankle, (b) additional stress 
was applied to the uninjured ankle while the football player walked or 
practiced, or (c) it may have been a purely physiological response on a 
paired limb. 
4. Dimethyl sulfoxide with fluocinonide had less severe side ef-
fects than did DMSO alone. Reduction of side effects of DMSO would pro-
vide another reason for physicians to prescribe DMSO with fluocinonide. 
Recorrmendations 
The following recommendations for future research are presented as a 
result of this study: 
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1. Another study should be conducted with an increased number of 
subjects. 
2. Replication of the study wHh the addition of a third treatment 
group is needed. The third treatment group would receive standard treat-
ment for sprained ankles with no dimethyl sulfoxide. 
3. Different strengths of DMSO and variations of different concen-
trations of fluocinonide need to be tested to find the optimal mixture. 
4. There is a need for additional scientific studies done on the 
uses and effectiveness of dimethyl sulfoxide. Because DMSO cannot be 
patented, future studies will have to be carried out by independent re-
searchers. Large pharmaceutical companies tend not to do research unless 
they can control the market and the price of the drug. 
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Package Insert Information 
·oomoso® · 
(dimethyl sulfoxide) 
Solution 
90% Dimethyl Sulfoxide 
Medical Grade 
GENERAL 
Oimethyt aultoxlde (OMSO). '" oxktatlon product or dlmlthyl aullkM. la '" exceptional tolvent pot..aslng a number or commercial uMt. 
OMSO ia the Jow•t member ol the group of elkyt aullo1ddea wilh a gener .. IOtmula of RSOR. Ita 
structural formula Is: 
CHa·S.CH• 
n tr .. ty mixes with wtler with the ewotuUon ol hMt 1nd lowers the lr•dng poinl of aqueoua aolu· :~:~.·~~:: ::!t n:~,:;~~~ro~.~ =~i::n":'~-::.o:~~~.:~~tJ~~;: 
carbons aa well aa W,organic ultsand nltrog.naeont-'nlng compounda. DMSO hM a high dielectric 
eonatant due 1o the polerlty or the aulphur~xygen bOnd. Its buiclty Ia alighny gr .. ter lhan w1tet 
due 1o enhanced electron denaity et the oxygen atom. n forn'll cryataMine Hits wUh attong protlc 
aclda 1nd coordltwilea wtth L1wia acids. II rnodiU" hydrogen bondtng. 
OMSO il a hygrotcoplc atabfe organic Uquid naentlalty odorLe .. and w11er white In cotOf'. Other 
physical charactertsties 6nclude: 
EE!::E~~~ :::: :~ :::: :~·:: :::::::::::::: :·~:: :::: !!J~-c 
Each ml of Oomoaofl' Solulion Veterinary contains to.O'M. dimelhylaulfoxide and 10.0% water. 
METABOUSU 
Oimethyt sulfoxide when administered topically or orally it rapidly absorbed and distributed ;, 
living matef'~l. 
Using Sts·tabeted OMSO (1) the maximal blood concentration alter cutaneou1 application was 
achieved In approximately 10 mlnuteain 1111 and t .. a than t hour In dogs. in rats and dogslha IUb-
ttanc:e dk1 not accumulate In the organa bullha concentration In the treated lkln and underlying 
mu1cle wa1 Increased. The main route ot excretion 11 via the urine partially depenclanl on the 
apecin and route of appflcallon. In rat1 there wu no lignltlcant dlllerance In the eNmlnaUon half 
t lma of 8 to I houri alter lntravanout ot cutanaoua .cSmlnlltration; In the dog, the elimination 
half Ume waa 1.5 to 2 daya after Intravenous or oral tdmlnlalration. In tha dog, however, afttl 
cutaneous appllcaUon aboul 55% or the administered material was ellrNnatad within 14 days. The 
radioactivity eliminated wla the lungt. and idanlifled at dimethyl tullide, was about 3% of the 
adminiala~ doN. 
In another su:a.beled study (2) with OMSO, Sollowlng Intravenous or cut.aneoutldmkt .. tratlon, tha 
only metaboUle detec:&ableln the urine ol humans and rata, •• dlmethyliUIIOAII (OMSOa). 
In anouwr S._labelad rat atudy (3). OMSO wu administered by the oral, intraparllonaaland der· 
::! ~~~~ .... ~~~ o~::O~f~.:~~.~t=t.~~\:e'::.a:~~:.:::::m~~:;~e~:::::a~~= f~enr~~r~':~.~~tr:n:~~-:c!Z: ~~~~~ ~~·~ f:,~=·-r.:-st7~'!'!:i~~ as~~~ 
7'% of the labeted dosage in all CIMI. 
A. peculiar sw .. tllh OdOf was nolad in the exhaled breath of cats treated with dimethylsulfoxide (4). The compound rnponsibta lor this was ldanlilied as dlmalhylaultkH. The ume odor hal Nan 
noted in all apeciel treated with the compound. 
In rabbits, dimelhyt IUitone was detected in the urine toHo~ng treatment of OMSO (5). 
It has been shown tNt dimethyl sulfone Ia a comtituent of normal cow'• milk (8). 
PHARMACOLOGY 
The or;ginal biotogk:al applications of OMSO wera ptlmarlly conlined to its uae in pr ... rving vari· 
ous tissues and cellular elements including b$ood (7). blood cella end bone marrow (B).Ieukocytn (i). lymphocytes {10), platelell {11),tpermatozoa (12. 13. 1-4), corneal grafts (15. 16). akin (17). tiiiUa 
culture calli (11. 19, 20. 21) and trypanosome• (22). by freezing techniqu ... OMSO has lllao bean 
Investigated as a radioprotective agent (23. 2-4). 
In early studies wilh planll It was claimed that OMSO exerted a profound ellect on the biologic 
membrane. altering lhalr naturai .Miactivity and enhancing the pent~trat'on ot anUtMotke ancl 
fungk:kS" (25). 
In one of lhe first atud6aa reported In animals, various drugs ware added to 15'% aolullon of OMSO 
lnatiltld Into the urinary bladder of Intact. anesthetized dog a through wtllch an enhancement or =~~:~:.~~ .. ac~::or::~~':!c(t2~)~~~~zi~!:'.m!: ';!!:~~~~a't':.tr:::::t :!r~hj~~~+:;:~ 
decreaN In blood sugar teveta over that of controll (2t). 
In vivo and In vilro methods demonstrated that OMSO enhanced human percutaneous at.orptlon 
ot various compounds Including steroids. vaeoconltrlcWFI, anllpertplrantt and dyea. u well aa an 
anthtMmlntlc (thlabenduota) and a akin antla.ptk (haxachiOf'ophene) (27, 28. 29, eo, 81, 82). En. 
hanc:ament was not due 10 irrevarwible dafn8ga to lhl stratum ccwnaum (21). 
OMSO haa bean stated 10 increasa tha penetration ot tow molecular wa~ht anargana such 11 
penicillin G but not large molecular weight altaroena auch u houN dust (30). 
Tha rate of paauge of tJitiated water kt lhe pr ... nca of OMSO on the epidarm&a ot lha hah1au 
mou• wae mauured In vitro. OMSO did not appear to promote the pa111ge of water by Ita pta• :~ad ~t 1~ha:!t~~~~~':!;! 60~'!,~f.~1~:'c::!d:r~h~~~~=~~u~'!r~,;;oe :'.!d ~~d mo11 s6gnllicant !han tha lima of axposute in utablllhlng the effect on the watlf barrier 
When tha tai ls of mM:a ware Immersed In • 5"" solution of varjOua psychoactive drugs 6n OMSO. ;::g~~ ~=-t!r~:v::r:x::~~~~~=,:'~~~=~::r~:~f.!:t,~C:,·ri~t!~:~:~~~~ 
water, al80 appeared to permit aoma drug penetration In tNa atudy (32). 
Using ten quaternary ammonium utts aa test compounds and eUtlef water or OMSO u solvents. 
tha oral LOse val ues wate determined in rats and mice. Toxtclty chang• ware obtained k\ some 
instancn by 50% OMSO and more changea were oblefWd In rats thaln mice although lha resulll In tha two apeclea wera not tlways parallel. When toxlclly waa altered by OMSO it lncraaaad in all 
instances except one (33). 
When adminiateJed systemically in another study. however. vark»ua druga di11ohfad In OMSO did 
nol differ aignilicanlly tn their lethality or catlular penetration aa eompared to the a.ama drug 
administered in saline (34). 
When evaluated as a sotvant f01 bk»toglc tcraaning teats. lOw dOMa of hormonaaln OMSO atlmu· 
lated a Jeii)OnM tknilar to that of the hOrmone in tha control vehicle. Higher dout ot hormone. 
however. failed to give the expected ratpOnae, suoqeating a partition coafUcMint in favOf or the 
solvent (35). OMSO w11a also lhown IO carry phyaost•g•nlne and phenylbutazone through the akin 
of tha rat (36). 
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The abaorpiton of phenylbutuon• dlqolvtld In an aqueoutsolutlon of DMSO wu !~aired wMn 
administered orally to the rabbit. Absorption of the same drug was not· improved using the aub--
cutaneous route simultaneously with OMSO. 
However, phenylbutazone could be delocled In robbll's bloOd lor soveral hours w~en an ointment 
containing OMSO and 5°/e phonytbutazone was applied lo the skin. When the DMSO content ol the 
ointment was lncro;;;ased, the phenylbutllZone levels increased. An lncraasa of phenyl~utazona In 
the muscle tissues underlying the silo ol application over a control ointment contammg phenyl-
butazone without OMSO could be demonstrated in rats (37). 
When 1% l!uorescein was injected lntradermally at several diff1rent concentrallons of OMSO_ in 
man. the dermal clearance of this substance Wis. considerably decreased IS compared to saline 
control solutions. This WIU!o be\levad due to reduced diffusion through the_dermil (29). 
The addilion of soo~ DMSO to solutions containing 1% old tuberculin (OT} aboll$hed positive patch 
test reactions in tuberculin sensitive human.subjects, and 50% OMSO IISO prevented lht c;~ermltltia produced by 1% trypsin. A possible explanation of these phenomena iathelorl'flatlon_of compltXIiS 
with protelnt causing their denaturation (28). OMSO has also been reported to alter the Schwartz· 
man reaction (30). It is believed that. similar to chelating agents. DMSO can form compleKaa with 
certain metallic salts (25. 38). 
· 
Based on the above evidence as well as gas chromatographic and radio·lsotopesludies It It estab-
lished that OMSO can ertectivelv penetrate the stratum corneum of the epidermis and enter the 
systemic circulation. OMSO also has the ability to allow some substances ·ordinarily unable to 
penelriile the skin barrier to be carried through it. The mechanism of penetr1nt action Ia not yet 
understood allhouQh some theories have been advanced a1 explanations (25, 38). 
DMSO has been claimed to show anti-inflammatory activ1ty .a.g1inst th~ biker's yeast. granuloma ~"o~~~"eeead~~g1~ :~~e~~~~e;~r:/fei~::~=~~~='~g~?:~~~\r~~~ ~~~~~~~~~~J~a:~\~~(~9).rats. The 
In a number of other studies in experimental animals (32, 36; 440) where DMSO hcia. b.een chl_elly 
administered orally or by injection, no antl-inllammatory or analgesic activity coulc:' be established. 
Following experimental hypersensilizalion to human gamma globulin In the horae, antigen chal· 
lenge resulted In ma:sslve erythoma, necrosis and slough. Thla re~cti_on could be markedly reduced by the hourly appllcalion at undiluled DMSO lo the reaction aile, 1fter challenge (30). 
In the human, OMSO did noteurt any beneficial effeCts on eKperimentally Induced thermal burns, 
contact dermaUtls or ullraviolet burns. It was noted in this study that the burns were of .I non-
intected nalura (28, 29). 
In experimentally Induced thermll edema of the legs of rabbits, the leg volume WIS the·18mt lor 
DMSO treated and untreated Oroups at 3 and 24 hours. but tets 1t 6 hOurt for the treate~ grcii.Jp. 
The DMSO In this experiment was applied at a site distant to the-Injury (30). · · · 
~~~f;~~:~~~~:saevr~rnee~~~e0!~~ib~~~f~h~~~Wa·v~~~~ ;~~ ~~~~~:~~~~~ !\:~2 ~8{.k,0 dosage 
DMSO, by itself. at concentrations of 100%, 66°/ •. and 33,-•• has been shown to produce neurolysis 
following perineural injection in the rat's sciatic nerve (41). 
The conflicting reports cited •bove lor the anll·lnllammatory 1nd analgesic properties of DMSO 
· are partially dependent upon the experimental models and methOds used to m·eaSure thHt 
parameters. DMSO falls to show analgesic or anll-inflammatory activity In certain of these situa-
tions. particularly when used by the systemic route or when administered topically preceded by 1n 
Irritant substance. In clinical studies in the horae, It was noted that when iodlne,linimantsorother 
strong Irritants were present on the skin from previous therapY and DMSO applied, a temporary 
but marked local reaction would occur. This was due to the lblllty of DMSO to carry these aub--
stances Into the underlying skin tissues where their Irritant 1ction1 could be displayed. When 
OMSO was used clinically, II was applied topically to the Involved .rea, while In the experimental 
situation this procedure was seldom used. In clinical situ1tlons, a marked reducUon of pain •nd 
edema has olten been noted following topical application. The mechanism of .action, 811hough not 
understood, may be partially related to the heat of dissolution of DMSO. It has been demonstrated 
that following cutaneous application or DMSO in dogt; the skin, dermla 1nd u~de~lying rouscle tiuuea ahow • local rise In tompeFiture (30). · ·. 
The analgesic and antl-lnflamm&tory •ctlvit'y of DMSO, as observ8d cllnic~lly arid the differences 
noted by classical pharmacological methods, may be partially due to the ability of the! compound 
to aUer the underlying pathology of the dtsease ttate under treatment (42). 
Using the isolaled guinea pig heart It was found that OMSO did not influence the amplitude ol 
cardiac contractions. heart rate, or coronary flow, although high Intravenous doses in the rat and 
cat reaulted In a transient lowering of blood pressure (36). 
~~!f~a~ndn~:r~::~ ~~~~!t?tf~~~~~~~~ :!~~a:~dud:~~~a~~dle~~~~!~~~sb~~~~~~a:~~~~!::!; 
llimulatlon and also caused spontaneous skeletal muacle fasclculations. Actual contraction amplitude 
was augmented aUhough contraction rate appeared unaffected. Vagal threshold was lowered 11most 50% by a bath concentration of 6% OMSO. The fasclculations and increased tone ol skeletal muscle, 
and lowering ol the va~al threshold by OMSO could be due to cholinesterase inhibition (43). Intravenous doses of 50% OMSO •n doses as high as 1 gJkg lailod to aUer the EKG ol anesthelized dogs and mon· 
key& (26). 
With iingte intravenous doses ol 200 mg/kg of DMSO to anesthetized cats, apnea and a transient fall 
In blood pressure ware produced. Subsequent doses caused only a transient hypotension and apnea 
was no longer observed. Vagotomy failed to influence the course of DMSO-Induced hypotension and bradycardia but atropine (1 mglkg) significantly 11tenu•ted these effects. Repeated intravenous adminis-tration ol DMSO where each succeeding d056 was doubled, led to • gradual!~ low~t~ed blood pressure 
until death ensued at about 4 glkg. Myoneural transmission, ganglionic transm•ssion 1nd lotceol cardia 
contraction also deteriorated gradually with repeated doses until death. The transient tall in blood pres· :u~~gc=: ~lfM$61~~ht~~i~:=~~~~:~~~~~nJ==~~~·o?~e~~ :"it:~~:h~~~~~~~=~~~f, 
TM In vitro oxygen consumption of liver, brain and hemldlaphragm tissues of r1t1 Ia not affected by !~P~~~·:endno~~:~~~~~~~~t~~e~~~~~~~~s~~~~. ~~":,~~~ ~u~g :~e Zo~~~~f:~~h'e y~e:~~O 
metabolism ol corticosterone by rat liver aiYces Is not alleclod by the Intravenous admlntstralion of 100 
mg DMS0/100 g body weight during 3 subsequent daya (2). 
OMSO treatment administered intraperlloneally to raft lor 35 daya decreased experimentally 
Induced Intestinal adhesions by 80% over controls aa compared to saline, corllaone acetate or 1 
combination of cortisone and DMSO ldmlnlstered aeparately (45). 
In rabbits, the application or 70% DMSO, 1djacent to but not on the wound Incision &Itt '-ppeared 
to increase the dc.velopment of wound tensile strength over controlt (46). · ·' 
Increasing the cOncentration of OMSO resulted In an Increasing inhibition of flbrObla$1 prolifera-tion in vitro, which was reversible (30). 
There Ia an Increase in urinary production following the dermal or .systemic 1dmlnistratlon of 
DMSO. 1nd • tr~nalent doubling of urine volume •ltlilr the inlravenoua administration of the drug (-48), 
Some studies have indicated" that DMs·o mey potentlale the action of certain compounds Includ-
Ing insulin (39), endogenous steroids and others. It was suggested lhat In the case of steroids it 
might be due to Improved penetration at their altes ol action on lysosomal membranes (30). 
The minimal inhibitory concentration (MfC) of OMSO to the nearest 10% was determined lor two 
isolates each ol Staphylococcus aureus, Staphylococcus au.reus var. albus, fl-hemolytic Strepto· 
cocci, Corynebacterium acnes, Corynebacterium specisa, Alcaligenes faecalis, Escherichia coli 
and Proteus species. Twenty percent DMSO was found to be bacteriostatic. For Staphylococcus 
aureus, the bactericidal cor:'centralion of 50".4 was 2.5 times that of the MIC; for the remainder, It 
ranged from 30"1. to -40"/e .wtlh the gram negative bacteria being somewhat more SUiiCeptible (29). 
No growth of Staphylococci, Pseudomonas or Escherichia coli occurred in the presence ol36% 
25°.4, 33o/. or greater concentrations, respectively, of DMSO (449). / ' 
T~e minimal inhibitory concentration ol DMSO in Sabouraud's broth to the nearest 10% was deter-
m!ned for three .dermatophytes: Trichophyton mentagrophyles, Microsporum gypseum, and 
Mtcrosporum cams. Ten percent 'OM SO was inhibitory to all three species. The fungicidal concan-
48 
tratlona werll 30% lor the Microsporum apecl•, while T. m.ntagrophytiiiiUIViv.ci the h!gh11t l•at 
concentration• of 50% (29). 
TOXICOLOGY 
Ab80rptlon ol topicnlly nppliod OMSO rosulia In dogmnulnlion ol lha rnnst coils nl tho silo ol 
application and a release of histamine followed by characteristic histamine wheallng oft he over~ 
lying skin. Following repeated applications of the compound to the same skin area, the mast cells 
are eventually depleted and the wheal no longer occurs (28). 
The erythema of the skin following topical application of DMSO Is considered to be partially due 
to the release of histamine. In addition, DMSO has the typlc'al action of most solvents In causing 
drying and defatting of the skin. 
In a study designed to evaluate the affects of Domosoa (dimethyl sulfoxide) Solution Veterinary at 
a total daily dose of 100~300 mi. administered for a total period of 90 days, no eMenti&l or clinically 
meanlngful·ophthalmologlcal effects were seen In the horse. There were no signlllcant variations 
in glucose, sodium, potassium, SGOT, or SGPT measurements. There were a lew fluctuations In 
hematologic values but no changes appear to be drug~related or of algnllicance. 
~~:~e:~~~t~:: ~~T~~~l~r.=~odpj~~~~~~ ~; g!~!~~1v~0~~~ ~:~~~~~~t~~:r,.:~~ 
ophthalmological effects were noted. No significant variations were ObseNI!d In biQ9d measurements, 
including glucose, BUN, SGOT and plasma electrophoresis. HematolOgic value• were similar to contr~ 
animals used in this study. · · 
Long~term topical applications of the drug to guinea pigs resulted In histopathologic changes 
similar to those observed In allergic contact dermalltls.-The obaervld clinical changes were com~ 
patible with either an allergic contact dermatltla or a primary Irritant effect (50) .• OM~O was shown 
to cause erythema and blistering of human and rat skin resulting tnlncreased permeabili~ of 
venules and capillaries (51). · 
In most cases the local irritation of the skin characterized by erythema, veSicle or blister formation 
and scurfing abates even with continued treatment. This phenomenon haa -been described· as 
"accommodation" or "hardening" olthe skin, and has been noted with other solvents. 
The undiluted compound has low systemic toxicity but a marked local necrotizing and Inflammatory el· 
feet when it is Injected subcutaneously. In rats the subcutaneous injection of 10 g/kg Of the intravenous 
injection of 2.5 glkg of undiluted OMSO lor 2 weekS-showed no definite Indication of systemic toxicity. 
The lOCal necrotizing effects produced at these dose l~yels, howe~r. prevented a longer period oltreat· 
ment. No significant hematologic or biochemical ch3nges were noted in 3 dogs receiving 0.4 g/kg_ for 
33 days (35). . 
Four dogs were administered topical OM$0 at 1 g/kg body weight, 5 days weekly lor 18 months. Serum 
r~~~~~~:~=~~~:~~~b;/~~~ .. <~?a?~~ua~~~~~fnPJ~~~r~Gi~;~~~~~s~~·Jr~~t~~~~b~~ 
{BUN) were determined at the beginning of treatment and at mC?f~thly intfirvals. Significant abnormali· 
ties did not occur (39). 
Upon iOjeclion "or OMSO lrito th"e rat pleura. there .is an ~ccumulation of fluid, lnitiall)' appearing 
as a transudate, but later as a proteln~rich exudate. Exudate formation Is thought to be due to 
increased vascular permeability. predominantly in venules, brought about by a delay_ad release of 
histamine together with activation or a vaso-active slow contracting substance (51). 
Rats are orally dosed 5 days a week lor2 weeks at levels of 1, 3.5. 5 and 10 mg/kQ of OMSO. The 
only deaths in this group were due to dosing injuries. No signs ol dermal sensitization were noted 
following a course of intradermal injection of a 1D-/o Vtv aqueous so_lution ~f O~SO in guinea 
~:Pu~'e~~r~~~~~~es:14,~9:~~~~ofr~ewb:~gknt5~~ injury lollowmg 28 da11y applications of the un· 
A compilation of !he results for a number of acute toxicity (LDso) determinations derived from 
several published reports (35, 52, 53, 54, 55} In several experlmental•nlmal apecleaare •s follows: 
Species 
Mouse 
Mouse 
Mouse 
Mouse 
Rat 
Rat 
Rat 
Dog 
Guinea Pig -
Chicken 
RL or Admlnlalr. 
sa 
IV 
Oral 
IP 
IV 
Oral 
IP 
IV 
IP 
Oral 
LD0 g/kg 
- 13.9 -20.5 
- 3.82-10.73 
- 1S.C ·22 
- 20.06 
- 5.25· 5.36 
- 15.0 -28.3 
- 5.5 • 13.621 
- 2.5 
- 5.5 
- 12.5 
Hemolysis resulting m hemoglobinuria and melhemoglobinuna was noted in anesthetized cats 
follow1ng single intravenous doses of 200 mg/kg OMSO. The Intraperitoneal administration of 
OMSO or ttle dilution of OMSO w11t1 isotonic saline prior to intravenous administration reduced 
its hemolytic activtly. (44). 
Tests In vitro showed that washed rabbit erythrocytes are hemolyzed in a short time with 40% to 
60% DMSO solution. Higher concentrations caused, without hemolysis, an agglutination of the 
erythrocytes (55). 
Teratology 
The intraperitoneal administration of 5.5 g/kg ol DMSO as a single dose to pregnant hamsters in· 
duced developmental malformation of their embryos (56). Both dimethyl iullox1de and diethyi 
sulfoxide are .teratogenic when injected into the c. hick embryo, the classification of matlor· 
mations being dependent upon the staJJe ol embryon1c development at the ti~e of treatment. ~he 
same drugs when administered by vanous techn1ques to mice, rats and rabb1ts in which fertl,ity 
had been established did not cause any embryonic malformations {57). 
Ocular Etlecla 
In a variety of experimental animals Including rats. dogs, swine, rabbits and primates, following 
oral or topical administration of DMSO, certain eye ctianges have been noted. These consist 
mainly of a change In the refractive index of the lens described as a "lens within a lens." The lens 
changes are characterized by a decrease In the normal relucency of the tens cortex, causing the 
normal central zone of the lens to act as a biconvex lena. When viewing the fundus of affected 
animals, it Is necessary to Interpose biconcave lenses In order to~· the retinal vnaels clearly. 
rhe functional effect would be • tendency toward myopia (58) •. 
The lens changes were first observed in dogs receiving 5 ~kq after 9 weeks of administration. At 
~a~:ro~~~~~~e~~~~~a~~~~~g ,;:~~~'O~~~h}~~~d~~ !~~ J~~hf~~~a~~~~1d~::~~ ~~~e~e~~ 
In swine, dermal application of 4.5 g 90%0MSO/kg twice daily caused stmllar lens changes by 90 
days of treatment {59). 
The lens changes appear earlier with oral administration, and also bear • relation to lhe dosage 
employed; the higher the dose the more rapid their appearance. · . 
The eye changes are slowly reversible but with .a definite ape'cles dllf8rence, the dog being the 
slowest to exhibit improvement. 
~t~~~f~i~ 1i~~~~ee S:Y~~ ~~~~~~~ r~~g~~ ~~f~~:!~~g!aS::~t~~u~~se:~r~.~~~~~0ti,2'g;;gt~~~~ 
we1ghl per day for s1x months. Aab~11s _which received dally doses as high as 10 g/kg orally or 
topically showed lines of d•scontmull)' m the1r lenses. No cataract was seen after ten weeks ot 
such daily treatment, although discontinuous lens lines could be deaected in about two weeks by 
~:~t1~~gfeuxr:~~~~~:~rh;~~=~ir~~~a~~~i~~noo"at~;~~e(j~)ses revealed reduct1on 1n the usual concen· 
INDICATIONS 
CANINE AND EQUINE 
Domoso• (dimethyl sullol'tide) Solution Veterinary, is recommended ali a topical applicaUon to 
reduce acute swelling due to trauma. 
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DOSAGE AND ADMINISTRATION 
Domoso• (dimethyl aullmdde) Solution Veterinary, Is to be admlnlatered topically to the akin ovor the 
alfected area. The spray pump should bli Jnllially held approximately 8 Inches from the animal ~nd the 
distance edjusted to provide a uniform coverage or the area. The volume delivered by depress1ng the 
spray pump is apprmdmately 14 mt. Refer to uaer precautions belOW" under "PRECAUTIONS ANO 
CONTRAINDICATION$.'' 
Dog a 
Uberal·applicatlon should be administered three to four times daily. Total dally dosage should 
not exceed 20 mi. Total duration of therapy should not exceed 14 daya. 
Hor ... a 
Liberal application stloutd be administered two to three timet dally, Total daily dosage should 
not exceed tOO mi. Totat duration of therapy should not ••ceed 30 days. 
SIDE EFFECTS 
In general; adverae reactlons·are local,·and'whlla they may prove 10 be annOytng to soma patient' 
they are- usually not of 1 serious nature. Upon topic•! application, an occasional animal may 
develop transient erythema, associated with local "burning" or "-smarting." Even when erythema 
or vesiculation occur, they are self-limiting reversible states, and not nece111.rlly an indlcaUan to 
discontinue medication. Dryness Of the skin and-an oyster-Uke breath odor have bt!en reported, 
Jhhee~:~~~~~f~! ~~e~~r~~:7e~;~.-;~en:~ec~~~~~~~a~0c~~a~c:~:: g:~e~se:~:d ~a;.~~~~~ 
with the use of this drug. This appears to be related to dosage and dural ton of therapy. 
PRECAUTIONS AND CONTRAINOICATIONS 
Contact between Oomoso Sotulfon and the skin should be avoided.' Rubber gk>ves should be worn while 
applyinB this drug. Forceps and swabs may be used to facilitate application. II Bbiorbed through the 
skin, Oomoso Solution will cause odorous breath and unpleasant mouth taste. Mild sedation or drowsi· 
ness, sensations ol warmlh, burning, Irritation, itching and mild erythematous localized Of generalized 
dermatitis have been reported in some persons following exposure IO·Oom~ Solution. Treatment of 
such side effects is symptomalic. Consult 1 physician immediately II adverse etfa:cta appear. 
Oornoso Solution Velarinery may mask certain di"Jease signs such as are seen In fractures etc.; this 
does not obviate the need lor specific lherapy In such conditions. Domoso should not be used directly 
prior \O racing or othor physical s\ross wherein tho drug might mask existing pathOlogy, such as a lracture. 
Since Oomoso Solution Veterinary ello~tivcly altor tho biol~ic mom'brano, it will in some cases lacili· 
tate the systemic absorption of other topteally applied drugs and may have a polentlatlng effect on drugs 
=t•r:gp~:::'~f~~~::;:~t~heg~~::r~l:~i1tdv!1a~~~~y ~. o:s~ ~~~::rvd~r ~~~~~ 
ICals lhrou~h lha dermis into the general circulation. II other topical medications are indicated the¥ should 
~~ ~p:~e~~~~!l ~fe~r~gtl:l~t~~:p~f~!~~:~!S ~~~~uJ'~~y ~~a~~:~i~~Yo?~:.;~~~.heet o re:,ot.u-
Domoso Solution Veterinary should also be judiciously used when administered In conjunction with other 
b';;SQa,;.~~~~:.f~:~:~~~':;~~~Ft;~t~rr~~~:.~~~~:;~~ ~~~:!~!V:~~~:~;;,d.:n~~rrt~r::'g,~~~~~~~: 
~~~o~:~~~~~::r:~MsFo~~~:es:~:d:rac'~:;:~~~=~:e~ ~~ 
should not be used on d~s. or horses. simultaneGusly or within a lew days before or after treatment 
with, or exposure lo, chotmesterase-inhibiting presticides or drugs. · · 
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DESCRIPTION OF FLUOCINONIDE 
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Package Insert Info,rmation 
LID EX® 
(fluocinonide) 
Topical Solution 0.05°/o 
description 
LIDEX solution 0.05% Is intended for topical administration. The active 
component is the corticosteroid fluocinonide. which is the 21·acetate 
ester of fluocinolone acetonide and has the chemical name pregna·1, 
4·diene·3, 20·dione, 21· (acetyloxy)·6, 9 ·difluoro·11·hydroxy·16, 
17·[(1-methylethylidene)bis(oxy)]·.(Ga, 11fl, 16a)·. II has the follow· 
ing chemical structure: 
LID EX topical solution contains fluocinonide 0.5 mg/ml in a solution 
of alcohol (35%), diisopropyl adipate, citric acid and propylene glycol. 
In this formulation, the active ingredient is totally in solution. 
clinical pharmacology 
Topical corticosteroids share anti-inflammatory, anti-pruritic and 
vasoconstrictive actions. 
The mechanism of anti-Inflammatory activity of the topical cor· 
ticosteroids is unclear. Various laboratory methods, including 
vasoconstrictor assays, are used to compare and predict potencies 
and I or clinical efficacies of the topical corticosteroids. There is some 
evidence to suggest that a recognizable correlation exists between 
vasoconstrictor potency and therapeutic efficacy In man . 
. Pharmacokinetics 
The extent of percutaneous absorption of topical corticosteroids is deter· 
mined by many factors including the vehicle, the integrity of the epider· 
mal barrier, and the use of occlusive dressings. A significantly greater 
amount of fluocinonide is absorbed from the solution than from the 
cream or gel formulations. 
Topical corticosteroids can be absorbed from normal intact skin. In flam· 
mation and/or other disease processes in the skin increase per· 
cutaneous absorption. Occlusive dressings substantially increase the 
percutaneous absorption of topical corticosteroids. Thus, occlusive 
dressings may be a valuable therapeutic adjunct lor treatment of resis· 
tant dermatoses. (See DOSAGE AND ADMINISTRA T/ON). 
Once absorbed through the skin, topical corticosteroids are handled 
through pharmacokinetic pathways similar to systemically administered 
corticosteroids. Corticosteroids are bound to plasma proteins in varying 
degrees. Corticosteroids are metabolized primarily in the liver and are 
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then excreted by the kidneys. Some of the topical corticosteroids and 
their metabolites are also excreted into lhe bile. 
Indications and usage 
LID EX® (fluocinonide) topical solution 0.05% is indicated for the relief 
of the inflammatory and pruritic manifestations of corticosteroid respon-
sive dermatoses. 
contralndications 
Topical corticosteroids are contraindicated in those patients with a 
history of hypersensitivity to any of the components of the preparation. 
precautions 
General 
Systemic absorption of topical corticosteroids has produced reversible 
hypothalamic·piluitary·adrenal (HPA) axis suppression. manifestation of 
Cushing's syndrome. hyperglycemia. and glucosuria in some patients. 
Conditions which augment systemic absorption include lhe application 
ol the more potent steroids. use over large surlace areas. prolonged 
use. the addition ol occlusive dressings, and dosage form. 
Therefore, patients receiving a large dose of a potent topical steroid ap-
plied to a large surface area or under an occlusive dressing should be 
evaluated periodically for evidence of HPA axis suppression by using the 
urinary free cortisol and ACTH stimulation tests. If HPA axis suppres· 
sion is noted, an attempt should be made to withdraw the drug, to 
reduce the frequency of application, or to substitute a less potent 
steroid. 
Recovery of HPA axis function is generally prompt and complete upon 
discontinuation of the drug. Infrequently, signs and symptoms of 
steroid withdrawal may occur, requiring supplemental systemic cor-
ticosteroids. Children may absorb proportionally larger amounts of 
topical corticosteroids and thus be more susceptible to systemic toxici· 
ty. (See PRECAUTIONS-Pediatric Use). 
Not for ophthalmic use. Severe irritation is possible if fluocinonide solu· 
lion contacts the eye. If that should occur, immediate flushing of the eye 
with a large volume of water is recommended. 
If irritation develops. topical corticosteroids should be discontinued and 
appropriate therapy instituted. 
In the presence of dermatological infections. the use ol an appropriate 
antifungal or antibacterial agent should be instituted. If a favorable 
response does not occur promptly, the corticosteroid should be discon· 
tinued until the infection has been adequately controlled. 
Information for the Patient 
Patients using topical corticosteroids should receive the following in for· 
mation and instructions: 
1. This medication is to be used as directed by the physician. It is for 
external use only. Avoid contact with the eyes. If there is contact 
with the eyes and severe irritation occurs, immediately flush with a 
large volume of water. 
2. Patients should be advised not to use !his medication for any 
disorder other than for which it was prescribed. 
3. The treated skin area should not be bandaged or otherwise covered 
or wrapped as to be occlusive unless directed by the physician. 
4. Patients should report any signs of local adverse reactions 
especially under occlusive dressing. 
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5. Parents of pediatric patients should be advised not to use trght· 
fitting diapers or plastic pants on a child being treated in the diaper 
area. as these garments may constitute occlusive dressings. 
Laboratory Tests 
The following tests may be helpful in evaluating HPA axis suppression-
Urinary free cortisol test 
ACTH stimulation test 
Carcinogenesis, Mutagenesis, and Impairment of Fertility 
Long·term animal studies have not been performed to evaluate the car· 
cinogenic potential or the eflect on fertility of topical corticosteroids. 
Studies to determine mutagenicity with prednisolone and hydrocortisone 
have revealed negative results. 
Pregnancy Category C 
Corticosteroids are generally teratogenic in laboratory animals when ad· 
ministered systemically at relatively low dosage levels. The more potent 
corticosteroids have been shown to be teratogenic alter dermal ;,pplica· 
tion in laboratory animals. There are no adequate and well·controlled 
studies in pregnant women on teratogenic effects !rom topically applied 
corticosteroids. Therefore. topical corticosteroids should be used during 
pregnancy only if the potential benelit justilies the potential risk to the 
fetus. Drugs of this class should not be used extensively on pregnant 
patients. in large amounts. or for prolonged periods of time. 
Nursing Mothers 
It is not known whether topical administration of corticosteroids could 
result in suflicient systemic absorption to produce detectable quantities 
in breast milk. Systemically administered corticosteroids are secreted 
into breast milk in quantities not likely to have a deleterious effect on the 
infant. Nevertheless. caution should be exercised when topical cor· 
ticosteroids are administered to a nursing woman. 
Pediatric Use 
Pediatric patients may demonstrate greater susceptibility 
to topical corticosteroid-induced HPA axis suppression 
and Cushing's syndrome than mature patients because ol 
a larger skin surface area to body weight ratio. 
Hypothalamic·pituilary·adrenal (HPA) axis suppression. Cushing·s syn· 
drome, and intracranial hypertension have been reported in children 
receiving topical corticosteroids. Manifestations of adrenal suppression 
in children include linear growth retardation. delayed weigh! garn. low 
plasma cortisol levels. and absence ol response to ACTH stimulation 
Manifestations of intracranial hypertension include bulging fontanelles. 
headaches. and bilateral papilledema. 
Administration of topical corticosteroids lo children should be timrted to 
the least amount compatible wilh an effective therapeutic regimen 
Chronic corticosteroid therapy may interlere with the growth and 
development ol children. 
adverse reactions 
The following local adverse reactions are reported rnlrequently wrth 
topical corticosteroids. bul may occur more frequently with the use ol 
occlusive dressings. These reactions are listed in an approximate 
decreasing order of occurrence. 
Burning 
Itching 
Irritation 
Dryness 
Folliculitis 
Hypertrichosis 
Acneiform eruptions 
Hypopigmentation 
Perioral dermatitis 
Allergic contact dermatitis 
Maceration of the skin 
Secondary infection 
Skin atrophy 
Striae 
Miliaria 
overdosage 
Topically applied corticosteroids can be absorbed in sufficient amounts 
to produce systemic effects (See PRECAUTIONS). 
dosage and administration 
LIDEX"' (fluocinonide) topical solution 0.05% should be applied to the 
affected area as a thin film from two to four times daily depending on the 
severity of the condition. 
Occlusive dressings may be used for the management of psoriasis or 
recalcitrant conditions. 
II an infection develops, the use of occlusive dressings should be 
discontinued and appropriate antimicrobial therapy instituted. 
how supplied 
LIDEX"' (fluocinonide) topical solution 0.05%. 
Plastic squeeze bottles 
. 20 cc. NDC 0033·25t7-44 
60 cc. NDC 0033·2517·46 
Store at room temperature. Avoid excessive heat above 40°C (104°F). 
CAUTIPN.: Federal law prohibits dispensing without a prescnpt10n. 
1~1 SYNTEXI 
SYNTEX LABORATORIES, INC. <0 REVISED 
PALO ALTO, CA 94304 APRIL 1985 
02-2517-44-2 
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APPENDIX C 
NATIONAL ATHLETIC TRAINER ASSOCIATION 1 S LIST 
OF 99 INJURIES OR CONDITIONS THAT MAY 
BENEFIT FROM DMSO TREATMENT 
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1. Abrasions 
2. Abscesses 
3. Achilles Tendon Strain 
4. Achilles Tendon Tenosynovitis 
5. Achillobursitis 
6. Acne 
7. Acromioclavicular Sprains 
8. Adductor Longus Strains 
9. Adductor Magnus Strains 
10. Ankle Dislocation 
11. Ankle Exostoses 
12. Ankle Sprain 
13. Ankle Subluxation 
14. Anterior Tibial Compartment Syndrome 
15. Anterior Tibial Tenosynovitis 
16. Arch Strain 
17. Arthritis 
18. Baseball Finger-interphalangeal contusions 
19. Bicipital Tenosynovitis 
20. Blisters 
21. Brachial Pleus Traction Injury 
22. Bunion 
23. Burns 
24. Bursitis 
25. Calcaneocuboid Ligament Strain 
26. Carbuncle 
27. Carpometacarpal Dislocation 
28. Carpometacarpal Subluxation 
29. Cellulitis 
30. Contusions 
31. Coccygodynia 
3 2. Costochondral Spr.ain 
33. Costochondral Strain 
34. Contact Dermatitis 
35. Seborrheic Dermatitis 
36. Hematoma Aurus 
37. Elbow Dislocation 
38. Elbow Subluxation 
39. Epicondylitis 
40. Epidermatophytosis 
41. Extensor Digitorum Longus Tenosynovitis 
42. Extensor Hallucis Longus Tenosynovitis 
43. Fat Pad Contusion 
44. Felon 
45. Fibular Collateral Ligament Bursitis 
46. Finger Dislocation 
47. Frostbite 
48. Furunculosis 
49. Gastrocnemius Strain 
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50. Glenohumeral Dislocation 
51. Glenohumeral Subluxation 
52. Gluteus Medius Strain 
53. Gracilis Strain 
54. Granuloma 
55. Hamstring Strain 
56. Hamstring Tenosynovitis 
57. Heat Rash 
58. Hemorrhoids 
59. Herpes Simplex 
60. Hip Dislocation 
61. Hip Sprain 
62. Hip Strain 
63. Hives 
64. Hiopectineal Bursitis 
65. Hiopsoas Strain 
66. Impetigo 
67. Infrapatellar Bursitis 
68. Ischiogluteal Bursitis 
69. Knee Contusion 
70. Knee Dislocation 
71. Knee Sprain 
72. Larynx Injury (Contusion) 
73. Lumbosacral Sprain 
74. Lumbosacral Strain 
75. Lunate Dislocation 
76. Metacarpalphalangeal Dislocation 
77. Myositis Ossificans 
78. Nail, Subungual Hematoma 
79. Nail, Ingrown 
80. Nerve Contusion 
81. Neuritis 
82. Osgood-Schlatter's Syndrome 
83. Osteochondritis 
84. Osteochondritis Desicans 
85. Patellar Dislocation 
86. Patellar Tendon Strain 
87. Periostitis 
88. Peroneal Nerve Contusion 
89. Peroneal Tenosynovitis 
90. Plantar Wart 
91. Plantaris Strain 
92. Tenosynovitis 
93. Muscle Strains 
94. Sprains 
95. Insect Bites 
96. Stye 
97. Tarsal Tunnel Syndrome 
98. Carpal Tunnel Syndrome 
99. Tendonitis 
APPENDIX D 
INFORMED CONSENT FORM 
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INFORMED CONSENT FORM 
By signing this document you are agreeing to participate in 
a double-blind research study dealing with alternative treatments 
for sprained ankles. This study is set up so that no one 
actively involved in the investigation knows which of the two 
possible treatments you will receive. The two possibilities are: 
70% DMSO or 70% DMSO with a corticosteroid (a topical 
anti-inflammatory medication). The rest of your therapy will be 
the standard treatment for a sprained ankle. 
Immediately after injury you will receive fifteen minutes of 
ice and elevation. Your ankles will be measured in a volumeter 
and then one of the two treatments will be applied to the injured 
ankle. The DMSO is to be left on for twelve hours. The next 
morning your ankles will be measured and your injured ankle will 
receive a cold whirlpool for fifteen minutes, ten minutes of high 
voltage galvanic current with elevation and ten minutes of cold 
whirlpool. Finally, an elastic wrap will be placed on your 
injured ankle that is to remain on until practice. If you are 
able to practice,your ankle will be taped and you will receive 
another treatment after practice. If you cannot practice you 
will receive treatment during practice of cold whirlpool and high 
frequency galvanic current. Before returning home after 
practice/treatment, your ankles will be measured and you will 
receive another DMSO treatment which is to be left on for twelve 
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hours. In total you will receive three, thirty cc treatments of 
DMSO/or DMSO with the corticosteroid. Your ankles will be 
measured three times a day for three days. Additional 
measurements will be taken on the fourth and seventh days after 
the injury. The standard treatment, cold whirlpool and high 
frequency galvanic current, will continue until your ankle is 
healed. 
This research study will be supervised by Cary Couch, MD. 
Any adverse reactions from the DMSO or DMSO with corticosteroid 
will be referred to him for evaluation and treatment. Possible 
adverse reactions to DMSO have been reported to be: bad breath 
and taste, skin rash, headache, nausea, diarrhea and sedation. 
Possible adverse reactions to the topical corticosteroid have 
been reported to be: skin burning, itching, irritation and 
dryness. 
It is understood that your participation is voluntary and 
confidential. You may withdraw from this experimental study at 
any time. In addition to this consent form it is required that 
you read and sign the State Board of Health informed consent form 
consenting the medical use of DMSO. 
If you have any questions feel free to ask Jeff Fair (the 
investigator, phone number 624-5837) or Dr. Couch, (the supervising 
physician, phone number 624-1575) at any time during the extent of the 
study. 
SUBJECT DATE INVESTIGATOR DATE 
WITNESS DATE 
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WRITTEN INFORMED REQUEST FOR PRESCRIPTION OF DIMETHYL SULFOXIDE 
(DMSO) FOR MEDICAL TREATMENT 
OKLAHOMA STATE BOARD OF HEALTH 
Patient's Name Age Sex 
Address 
Disease, illness or physical condition supervised for medical 
treatment by Cary Couch, MD and administered by Jeff Fair, AT 
with dimethyl sulfoxide (DMSO): sprained ankle • 
My Physician has explained to me: 
(a) That the Federal Food and Drug Administration has deter-
mined dimethyl sulfoxide (DMSO) to be an "unapproved new 
drug" and that federal law prohibits the interstate 
distribution of an "unapproved new drug". 
(b) That neither the American Cancer Society, The American 
Medical Association, nor the Oklahoma State Medical 
Association, recommends the use of dimethyl sulfoxide 
(DMSO) in the treatment of any disease, illness or 
physical condition. 
(c) That there are alternative recognized treatments for the 
disease, illness or physical condition from which I 
suffer which he has offered to provide for me including: 
(Here described) 
Use of standard therapeutic modalities (rest, ice, com-
pression and elevation) for the treatment of a sprained 
ankle • 
Possible side effects: 
(a) Skin rash (erythematous scaling dermatitis) 
(b) Bad breath and taste 
(c) Headache, nausea, diarrhea and sedation 
Notwithstanding the foregoing, I hereby request prescription 
and use of dimethyl sulfoxide (DMSO) in the medical treatment 
of the disease, illness or physical condition for which I 
suffer. 
ATTEST: 
PRESCRIBING PHYSICIAN DATE SIGNATURE OF PATIENT DATE 
WITNESS DATE LICENSED ATHLETIC TRAINER DATE 
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DMSO MIXING FORMULAS 
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-DMSO MIXING FORMULAS-
A) 70% DMSO FROM SO% DMSO 
70 ml of SO% DMSO plus 20ml of distilled wate~ -
SOml of 70% DMSO 
8) 70% DMSO COMBINED WITH FLUOCINONIDE 
70ml or SO% OMSO plus 20ml o~ .05% Fluocinonlde • 
SOml or 70% DMSO with _1_% concent~atlon or 
Fluoclnonlde 
20ml X .OSgm • .Olgm 
100ml 
.Olgm X 100ml 
SOml -
.01% concent~atlon of 
Fluoclnonlde in the 70% DMSO 
APPENDIX G 
ANKLE INJURY RECORD SHEET 
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ANKLE INJURY RECORD 
NA~---------------------------- SPORT ---------------
INJURY DEGREE --- {1,2,3) BLOCK ___ .-. BOTTLE Prescription *·----
INJURY: YEAR MONTH DAY TIME 
RIGHT LEFT 
READINGS 
HOUR DATE WHEN PLT 11 RIGHT LEFT BY COI+IENTS 
Pre-Test L / 
Injury * 
12 morn 
20 pre 
24 * post 
36 morn 
44 pre 
48 * post 
60 morn 
68 pre 
72 post 
84 morn 
168 morn (1 week oost-1n.1urvl 
• OHSO App11cat10A 
** P • Practice T • Treatment Only 
APPENDI:X H 
ADDITIONAL STATISTI'CAL DATA 
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SUBJECT 
6/1 
1. 1652 
1542 
2. 1555 
1525 
3. 1490 
1471 
4. 1671 
1662 
5. 1503 
1492 
6. 1478 
1521 
7. ll05 
1098 
8. 1708 
1693 
9. 1455 
1438 
10. 1689 
1648 
11. 1232 
1229 
12. 1747 
1690 
TABLE V 
ANALYSIS OF VARIANCE ON INJURED 
ANKLE OVER TIME 
DATE 
6/2 6/3 6/4 6/5 
1624 1628 1639 1643 
1560 1549 1562 1572 
1566 1568 1549 1544 
1543 1543 1525 1530 
1518 1478 1518 1480 
1494 1469 1472 1454 
1679 1669 1676 1680 
1666 1687 1672 1673 
1515 1497 1486 1499 
1489 1500 1482 1490 
1501 1462 1491 1476 
1538 1515 1527 1541 
ll18 ll09 1098 ll01 
ll06 ll12 ll08 ll05 
1696 1712 1694 1712 
1681 1702 1683 1713 
1448 1444 1445 1454 
1426 1434 1450 1437 
1701 1712 1703 1707 
1655 1660 1663 1659 
1242 1251 1241 1253 
1243 1266 1246 1235 
1747 1744 1736 1745 
1681 1682 1686 1679 
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ANKLE 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
R 
L 
:C10URCE 
Tc•ta 1 
TABLE VI 
ANALYSIS OF VARIANCE ON UNINJURED 
ANKLE OVER TIME 
DF SUI1 SQUARES 
:l:l.9 
[iub .j 
Le?q 
:1. :1. 
:1. 
:1. :1. 
::; , 80?, .B3~S. :::!'7 
:to,E~67.~:;o 
29,250.30 
346~166.85 130.18 ** 
Subj*Leg (Error Al 
[)<;\'y'!C> 
Dc\'y'S'. l.. i. nE:E~r 0: D l ) 
l);,,y~.; Quad C DE'~ I 
Day~;; Cubic: ( D3 I 
Days Quartic CD4l 
Subj*Days (Error 8) 
:1. 
:1. 
:1. 
:1. 
Leg-*·Days :ll 
Leg*Dl :1. 
Lf_,,g·>-02 :l 
Leg*D3 :l 
Leq*Dt.; :t 
Subj*Leg*Days <Error Cl 44 
'·I·IJB .. ?fel. 
3LI ... 50 
1 L;E3. 00 
277.35 
El.86 
6,B69.88 
t.1.Lf'7. 75 
:l89.(lt.,. 
97 .~"50 
24.07 
1~:17.11.+ 
2,336.45 
* Significant at a = .05 
** Significant at a = .01 
NS Not Significant at a="05 
10,267.50 3.86 NS 
s~659" 12 
3L·~ .. 50 
148.00 
.277.35 
El. !:16 
'156. 13 
. 1D9.0lt 
97.50 
2l;. 07 
· :t3'7" 1 L; 
53.10 
0.22 
0.95 
1.78 
0 .Ot.:> 
:::!.5(;, 
:l "8£; 
0.45 
2.58 
Nf:> 
NS 
Nf.l 
1'18 
NS 
I'm 
NS 
NS 
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TABLE VII 
ANALYSIS OF VARIANCE ON BOTH ANKLES AND 
BOTH TREATMENTS OVER TIME 
OBS SUBv BLK BOTL TRT RGHTI LEFTI LGINv LEG HOUR TIME RGHT LEFT VOLDIF 
1 1 11 2 LYDX 1527 1520 LEFT SPRAIN INv 0 1521 1488 -32 
2 1 11 2 LYDX 1527 1520 LEFT GOOD INv 0 1521 1488 -6 
3 1 11 2 LYDX 1527 1528 LEFT SPRAHJ 012 12 1517 1526 -2 
4 1 11 2 LYDX 1527 1528 LEFT GOOD 012 12 1517 1526 -10 
5 1 11 2 LYDX 1527 1520 LEFT SPRAIN 020 20 1535 1540 20 
6 1 11 2 LYDX 1527 1520 LEFT GOOD 020 20 1535 1540 8 
7 1 11 2 LYDX 1527 1520 LEFT SPRAIN 024 24 1529 1513 -7 
8 1 11 2 LYDX 1527 1520 LEFT GOOD 024 24 1529 1513 2 
9 1 11 2 LYDX 1527 1520 LEFT SPRAIN 036 36 1498 1544 24 
10 1 11 2 LYDX 1527 1520 LEFT GOOD 036 36 1498 1544 -29 
1 1 1 11 2 LYDX 1527 1520 LEFT SPRAIN 044 44 1523 1530 10 
12 1 11 2 LYDX 1527 1520 LEFT GOOD 044 44 1523 1530 -4 
13 1 11 2 LYDX 1527 1520 LEFT SPRAIN 048 48 1492 1545 25 
14 1 11 2 LYDX 1527 1520 LEFT GOOD 048 48 1492 1545 -35 
15 1 11 2 LYDX 1527 1520 LEFT SPRAIN 060 60 1516 1560 40 
16 1 11 2 LYDX 1527 1520 LEFT GOOD 060 60 1516 1560 - 11 
17 1 11 2 LYDX 1527 1520 LEFT SPRAIN 068 68 1556 1540 20 
18 1 11 2 LYDX 1527 1520 LEFT GOOD 068 68 1556 1540 29 
19 1 11 2 LYDX 1527 1520 LEFT SPRAIN 072 72 1518 1554 34 
20 1 11 2 LYDX 1527 1520 LEFT GOOD 072 72 1518 1554 -9 
21 1 11 2 LYDX 1527 1520 LEFT SPRAIN 084 84 1541 1598 78 
22 1 11 2 LYDX 1527 1520 LEFT GOOD 084 84 1541 1598 14 
23 1 11 2 LYDX 1527 1520 LEFT SPRAIN 168 168 1545 1599 79 
24 1 1 1 2 LYDX 1527 1520 LEFT GOOD 168 168 1545 1599 18 
25 2 11 1 DMSO 1767 1773 RGHT SPRAIN INv 0 1719 1728 -48 
26 2 11 1 DMSO 1767 1773 RGHT GOOD INv 0 1719 1728 -45 
27 2 11 1 DMSO 1767 1773 RGHT SPRAIN 012 12 1778 1766 1 1 
28 2 11 1 DMSO 1767 1773 RGHT GOOD 012 12 1778 1766 -7 
29 2 11 1 DMSO 1767 1773 RGHT SPRAIN 020 20 1749 1745 -18 
30 2 11 1 DMSO 1767 1773 RGHT GOOD 020 20 1749 1745 -28 
31 2 11 1 DMSO 1767 1773 RGHT SPRAIN 024 24 1724 1766 -43 
32 2 11 1 DMSO 1767 1773 RGHT GOOD 024 24 1724 1766 -7 
33 2 11 1 DMSO 1767 1773 RGHT SPRAIN 036 36 1792 1770 25 
34 2 11 1 DMSO 1767 1773 RGHT GOOD 036 36 1792 1770 -3 
35 2 11 1 DMSO 1767 1773 RGHT SPRAIN 044 44 1757 1762 -10 
36 2 11 1 DMSO 1767 1773 RGHT GOOD 044 44 1757 1762 -11 
37 2 11 1 DMSO 1767 1773 RGHT SPRAIN 048 48 1774 1780 7 
38 2 11 1 DMSO 1767 1773 RGHT GOOD 048 48 1774 1780 7 
39 2 11 1 DMSO 1767 1773 RGHT SPRAIN 060 60 1775 1768 8 '-.1 
40 2 11 1 DMSO 1767 1773 RGHT GOOD 060 60 1775 1768 -5 CJ 
41 2 11 1 DMSO 1767 1773 RGHT SPRAIN 068 68 1772 1766 5 
42 2 11 1 DMSO 1767 1773 RGHT GOOD 068 68 1772 1766 -7 
TABLE VII (Continued) 
OBS SUBJ BLK BOTL TRT RGHTI LEFTI LGINJ LEG HOUR TIME RGHT LEFT VOLDIF 
43 2 11 1 DMSO 1767 1773 RGHT SPRAIN 072 72 1772 1768 5 
44 2 11 1 DMSO 1767 1773 RGHT GOOD 072 72 1772 1768 -5 
45 2 11 1 DMSO 1767 1773 RGHT SPRAIN 084 84 1735 1755 -32 
46 2 11 1 DMSO 1767 1773 RGHT GOOD 084 84 1735 1755 -18 
47 2 11 1 DMSO 1767 1773 RGHT SPRAIN 168 168 1754 1769 -13 
48 2 1 1 1 DMSO 1767 1773 RGHT GOOD 168 168 1754 1769 -4 
49 3 21 1 LYDX 1686 1751 LEFT SPRAIN INJ 0 1678 1693 -58 
50 3 21 1 LYDX 1686 1751 LEFT GOOD INJ 0 1678 1693 -8 
51 3 21 1 LYDX 1686 1751 LEFT SPRAIN 012 12 1722 1699 -52 
52 3 21 1 LYDX 1686 1751 LEFT GOOD 012 12 1722 1699 36 
53 3 21 1 LYDX 1686 1751 LEFT SPRAIN 020 20 1749 1704 -47 
54 3 21 1 LYDX 1686 1751 LEFT GOOD 020 20 1749 1704 63 
55 3 21 1 LYDX 1686 1751 LEFT SPRAIN 024 24 1808 1735 -16 
56 3 21 1 LYDX 1686 1751 LEFT GOOD 024 24 1808 1735 122 
57 3 21 1 LYDX 1686 1751 LEFT SPRAIN 036 36 1794 1775 24 
58 3 21 1 LYDX 1686 1751 LEFT GOOD 036 36 1794 1775 108 
59 3 21 1 LYDX 1686 1751 LEFT SPRAIN 044 44 1772 1753 2 
60 3 21 1 LYDX 1686 1751 LEFT GOOD 044 44 1772 1753 86 
61 3 21 1 LYDX 1686 1751 LEFT SPRAIN 048 48 1746 1734 -17 
62 3 21 1 LYDX 1686 1751 LEFT GOOD 048 48 1746 1734 60 
63 3 21 1 LYDX 1686 1751 LEFT SPRAIN 060 60 1758 1766 15 
64 3 21 1 LYDX 1686 1751 LEFT GOOD 060 GO 1758 1766 72 
65 3 21 1 LYDX 1686 1751 LEFT SPRAIN 068 68 1766 1778 27 
66 3 21 1 LYDX 1686 1751 LEFT GOOD 068 68 1766 1778 80 
67 3 21 1 LYDX 1686 1751 LEFT SPRAIN 072 72 1695 1716 -35 
68 3 21 1 LYDX 1686 1751 LEFT GOOD 072 72 1695 1716 9 
69 3 21 1 LYDX 1686 1751 LEFT SPRAIN 084 84 1752 1729 -22 
70 3 21 1 LYDX 1686 1751 LEFT GOOD 084 84 1752 1729 66 
71 3 21 1 LYDX 1686 1751 LEFT SPRAIN 168 168 1930 1842 91 
72 3 21 1 LYDX 1686 1751 LEFT GOOD 168 168 1930 1842 244 
73 4 21 2 DMSO 1686 1751 RGHT SPRAIN INJ 0 1759 1757 73 
74 4 21 2 DMSO 1686 1751 RGHT GOOD INJ 0 1759 1757 6 
75 4 21 2 DMSO 1686 1751 RGHT SPRAIN 012 12 1811 1747 125 
76 4 21 2 DMSO 1686 1751 RGHT GOOD 012 12 1811 1747 -4 
77 4 21 2 DMSO 1686 1751 RGHT SPRAIN 020 20 1842 1780 156 
78 4 21 2 DMSO 1686 1751 RGHT GOOD 020 20 1842 1780 29 
79 4 21 2 DMSO 1686 1751 RGHT SPRAIN 024 24 1843 1781 157 
80 4 21 2 OMSO 1686 1751 RGHT GOOD 024 24 1843 1781 30 
81 4 21 2 DMSO 1686 175.1 RGHT SPRAIN 036 36 1892 1797 206 
82 4 21 2 DMSO 1686 1751 RGHT GOOD 036 36 1892 1797 46 
83 4 21 2 DMSO 1686 1751 RGHT SPRAIN 044 44 1919 1814 233 
84 4 21 2 DMSO 1686 1751 RGHT GOOD 044 44 1919 1814 63 
-.....J 
TABLE VII (Continued) 
OBS SUBJ BLK BOTL TRT RGHTI LEFT I LGINJ LEG HOUR TIME RGHT LEFT VOLDIF 
85 4 21 2 DMSO 1686 1751 RGHT SPRAIN 048 48 1924 1820 238 
86 4 21 2 DMSO 1686 1751 RGHT GOOD 048 48 1924 1820 69 
87 4 21 2 DMSO 1686 1751 RGHT SPRAIN 060 60 1930 1842 244 
88 4 21 2 DMSO 1686 1751 RGHT GOOD 060 60 1930 1842 91 
89 4 21 2 DMSO 1686 1751 RGHT SPRAIN 068 68 1908 1838 222 
90 4 21 2 DMSO 1686 1751 RGHT GOOD 068 68 1908 1838 87 
91 4 21 2 DMSO 1686 1751 RGHT SPRAIN 072 72 1900 1814 214 
92 4 21 2 DMSO 1686 1751 RGHT GOOD 072 72 1900 1814 63 
93 4 21 2 DMSO 1686 1751 RGHT SPRAIN 084 84 1937 1777 251 
94 4 21 2 DMSO 1686 1751 RGHT GOOD 084 84 1937 1777 26 
95 4 21 2 DMSO 1686 1751 RGHT SPRAIN 168 168 1812 1727 126 
96 4 21 2 DMSO 1686 1751 RGHT GOOD 168 168 1812 1727 -24 
97 5 22 1 DMSO 1259 1247 RGHT SPRAIN INJ 0 1287 1253 28 
98 5 22 1 DMSO 1259 1247 RGHT GOOD INJ 0 1287 1253 6 
99 5 22 1 DMSO 1259 1247 RGHT SPRAIN 012 12 1329 1251 70 
100 5 22 1 DMSO 1259 1247 RGHT GOOD 012 12 1329 1251 4 
101 5 22 1 DMSO 1259 1247 RGHT SPRAIN 020 20 1318 1258 59 
102 5 22 1 DMSO 1259 1247 RGHT GOOD 020 20 1318 1258 1 1 
103 5 22 1 DMSO 1259 1247 RGHT SPRAIN 024 24 1378 1278 119 
104 5 22 1 DMSO 1259 1247 RGHT GOOD 024 24 1378 1278 31 
105 5 22 1 DMSO 1259 1247 RGHT SPRAIN 036 36 1368 1263 109 
106 5 22 1 DMSO 1259 1247 RGHT GOOD 036 36 1368 1263 16 
107 5 22 1 DMSO 1259 1247 RGHT SPRAIN 044 44 1323 1259 64 
108 5 22 1 DMSO 1259 1247 RGHT GOOD 044 44 1323 1259 12 
109 5 22 1 DMSO 1259 1247 RGHT SPRAIN 048 48 1306 1253 47 
110 5 22 1 DMSO 1259 1247 RGHT GOOD 048 48 1306 1253 6 
111 5 22 1 DMSO 1259 1247 RGHT SPRAIN 060 60 1325 1269 66 
112 5 22 1 DMSO 1259 1247 RGHT GOOD 060 60 1325 1269 22 
113 5 22 1 DMSO 1259 1247 RGHT SPRAIN 068 68 1293 1165 34 
114 5 22 1 DMSO 1259 1247 RGHT GOOD 068 68 1293 1165 -82 
115 5 22 1 DMSO 1259 1247 RGHT SPRAIN 072 72 1318 1254 59 
116 5 22 1 DMSO 1259 1247 RGHT GOOD 072 72 1318 1254 7 
117 5 22 1 DMSO 1259 1247 RGHT SPRAIN 084 84 1360 1290 101 
118 5 22 1 DMSO 1259 1247 RGHT GOOD 084 84 1360 1290 43 
1 19 5 22 1 DMSO 1259 1247 RGHT SPRAIN 168 168 1283 1240 24 
120 5 22 1 DMSO 1259 1247 RGHT GOOD 168 168 1283 1240 -7 
12 1 6 22 2 LYDX 1305 1287 RGHT SPRAIN INJ 0 1344 1291 39 
122 6 22 2 LYDX 1305 1287 RGHT GOOD INJ 0 1344 1291 4 
123 6 22 2 LYDX 1305 1287 RGHT SPRAIN 012 12 1345 1349 40 
124 6 22 2 LYDX 1305 1287 RGHT GOOD 012 12 1345 1349 62 
125 6 22 2 LYDX 1305 1287 RGHT SPRAIN 020 20 1354 1324 49 
126 6 22 2 LYDX 1305 1287 RGHT GOOD 020 20 1354 1324 37 
....... 
N 
TABLE VII (Continued) 
OBS SUBJ BLK BOTL TRT RGHTI LEFT! LGINJ LEG HOUR TIME RGHT LEFT VOLDIF 
127 6 22 2 LYDX 1305 1287 RGHT SPRAIN 024 24 1342 1261 37 
128 6 22 2 LYDX 1305 1287 RGHT GOOD 024 24 1342 1261 -26 
129 6 22 2 LYDX 1305 1287 RGHT SPRAIN 036 36 1338 1239 33 
130 6 22 2 LYDX 1305 1287 RGHT GOOD 036 36 1338 1239 -48 
131 6 22 2 LYDX 1305 1287 RGHT SPRAIN 044 44 1344 1310 39 
132 6 22 2 LYDX 1305 1287 RGHT GOOD 044 44 1344 1310 23 
133 6 22 2 LYDX 1305 1287 RGHT SPRAIN 048 48 1320 1316 15 
134 6 22 2 LYDX 1305 1287 RGHT GOOD 048 48 1320 1316 29 
135 6 22 2 LYDX 1305 1287 RGHT SPRAIN 060 60 1336 1306 31 
136 6 22 2 LYDX 1305 1287 RGHT GOOD 060 60 1336 1306 19 
137 6 22 2 LYDX 1305 1287 RGHT SPRAIN 068 68 1334 1298 29 
138 6 22 2 LYDX 1305 1287 RGHT GOOD 068 68 1334 1298 1 1 
139 6 22 2 LYDX 1305 1287 RGHT SPRAIN 072 72 1321 1293 16 
140 6 22 2 LYDX 1305 1287 RGHT GOOD 072 72 1321 1293 6 
141 6 22 2 LYDX 1305 1287 RGHT SPRAIN 084 84 1332 1311 27 
142 6 22 2 LYDX 1305 1287 RGHT GOOD 084 84 1332 1311 24 
143 6 22 2 LYDX 1305 1287 RGHT SPRAIN 168 168 1325 1319 20 
144 6 22 2 LYOX 1305 1287 RGHT GOOD 168 168 1325 1319 32 
145 7 23 1 DMSO 1690 1669 LEFT SPRAIN INJ 0 1673 1684 15 
146 7 23 1 DMSO 1690 1669 LEFT GOOD INJ 0 1673 1684 -17 
147 7 23 1 DMSO 1690 1669 LEFT SPRAIN 012 12 1702 1737 68 
148 7 23 1 DMSO 1690 1669 LEFT GOOD 012 12 1702 1737 12 
149. 7 23 1 DMSO 1690 1669 LEFT SPRAIN 020 20 1722 1745 76 
150 7 23 1 DMSO 1690 1669 LEFT GOOD 020 20 1722 1745 32 
151 7 23 1 DMSO 1690 1669 LEFT SPRAIN 024 24 1714 1753 84 
152 7 23 1 DMSO 1690 1669 LEFT GOOD 024 24 1714 1753 24 
153 7 23 1 DMSO 1690 1669 LEFT SPRAIN 036 36 1745 1766 97 
154 7 23 1 DMSO 1690 1669 LEFT GOOD 036 36 1745 1766 55 
155 7 23 1 DMSO 1690 1669 LEFT SPRAIN 044 44 1709 1704 35 
156 7 23 1 DMSO 1690 1669 LEFT GOOD 044 44 1709 1704 19 
157 7 23 1 DMSO 1690 1669 LEFT SPRAIN 048 48 1714 1719 50 
158 7 23 1 DMSO 1690 1669 LEFT GOOD 048 48 1714 1719 24 
159 7 23 1 DMSO 1690 1669 LEFT SPRAIN 060 60 1763 1780 111 
160 7 23 1 DMSO 1690 1669 LEFT GOOD 060 60 1763 1780 73 
161 7 23 1 DMSO 1690 1669 LEFT SPRAIN 068 68 1738 1773 104 
162 7 23 1 DMSO 1690 1669 LEFT GOOD 068 68 1738 1773 48 
163 7 23 1 DMSO 1690 1669 LEFT SPRAIN 072 72 1723 1747 78 
164 7 23 1 DMSO 1690 1669 LEFT GOOD 072 72 1723 1747 33 
165 7 23 1 DMSO 1690 1669 LEFT SPRAIN 084 84 1734 1756 87 
166 7 23 1 DMSO 1690 1669 LEFT GOOD 084 84 1734 1756 44 
167 7 23 1 DMSO 1690 1669 LEFT SPRAIN 168 168 1707 1713 44 
168 7 23 1 DMSO 1690 1669 LEFT GOOD 168 168 1707 1713 17 
""-J 
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TABLE VII (Continued) 
OBS SUBJ BLK BOTL TRT RGHTI LEFT! LGINJ LEG HOUR TIME RGHT LEFT VOLDIF 
169 8 23 2 LYDX 1547 1529 RGHT SPRAIN INJ 0 1592 1514 45 
170 8 23 2 LYDX 1547 1529 RGHT GOOD INJ 0 1592 1514 -15 
171 8 23 2 LYDX 1547 1529 RGHT SPRAIN 012 12 1725 1571 178 
172 8 23 2 LYDX 1547 1529 RGHT GOOD 012 12 1725 1571 42 
173 8 23 2 LYDX 1547 1529 RGHT SPRAIN 020 20 1712 1560 165 
174 8 23 2 LYDX 1547 1529 RGHT GOOD 020 20 1712 1560 31 
175 8 23 2 LYDX 1547 1529 RGHT SPRAIN 024 24 1705 1545 158 
176 8 23 2 LYDX 1547 1529 RGHT GOOD 024 24 1705 1545 16 
177 8 23 2 LYDX 1547 1529 RGHT SPRAIN 036 36 1675 1512 128 
178 8 23 2 LYDX 1547 1529 RGHT GOOD 036 36 1675 1512 -17 
179 8 23 2 LYDX 1547 1529 RGHT SPRAIN 044 44 1670 1539 123 
180 8 23 2 LYDX 1547 1529 RGHT GOOD 044 44 1670 1539 10 
181 8 23 2 LYDX 1547 1529 RGHT SPRAIN 048 48 1700 1526 153 
182 8 23 2 LYDX 1547 1529 RGHT GOOD 048 48 1700 1526 -3 
183 8 23 2 LYDX 1547 1529 RGHT SPRAIN 060 60 1615 1532 68 
184 8 23 2 LYDX 1547 1529 RGHT GOOD 060 60 1615 1532 3 
185 8 23 2 LYDX 1547 1529 RGHT SPRAIN 068 68 1628 1541 81 
186 8 23 2 LYDX 1547 1529 RGHT GOOD 068 68 1628 1541 12 
187 8 23 2 LYDX 1547 1529 RGHT SPRAIN 072 72 1617 1530 70 
188 8 23 2 LYDX 1547 1529 RGHT GOOD 072 72 1617 1530 1 
189 8 23 2 LYDX 1547 1529 RGHT SPRAIN 084 84 1584 1535 37 
190 8 23 2 LYDX 1547 1529 RGHT GOOD 084 84 1584 1535 6 
191 8 23 2 LYDX 1547 1529 RGHT SPRAIN 168 168 1597 1538 50 
192 8 23 2 LYDX 1547 1529 RGHT GOOD 168 168 1597 1538 9 
193 9 24 1 LYDX 1526 1524 RGHT SPRAIN INJ 0 1548 1521 22 
194 9 24 1 LYDX 1526 1524 RGHT GOOD INJ 0 1548 1521 -3 
195 9 24 1 LYDX 1526 1524 RGHT SPRAIN 012 12 1586 1542 60 
196 9 24 1 LYDX 1526 1524 RGHT GOOD 012 12 1586 1542 18 
197 9 24 1 LYDX 1526 1524 RGHT SPRAIN 020 20 1572 1536 46 
198 9 24 1 LYDX 1526 1524 RGHT GOOD 020 20 1572 1536 12 
199 9 24 1 LYDX 1526 1524 RGHT SPRAIN 024 24 1556 1534 30 
200 9 24 1 LYDX 1526 1524 RGHT GOOD 024 24 1556 1534 10 
201 9 24 1 LYDX 1526 1524 RGHT SPRAIN 036 36 1542 1531 16 
202 9 24 1 LYDX 1526 1524 RGHT GOOD 036 36 1542 1531 7 
203 9 24 1 LYDX 1526 1524 RGHT SPRAIN 044 44 1530 1526 4 
204 9 24 1 LYDX 1526 1524 RGHT GOOD 044 44 1530 1526 2 
205 9 24 1 LYDX 1526 1524 RGHT SPRAIN 048 48 1530 1522 4 
206 9 24 1 LYDX 1526 1524 RGHT GOOD 048 48 1530 1522 -2 
207 9 24 1 LYDX 1526 1524 RGHT SPRAIN 060 60 1541 1520 15 
208 9 24 1 LYDX 1526 1524 RGHT GOOD 060 60 1541 1520 -4 
209 9 24 1 LYDX 1526 1524 RGHT SPRAIN 068 68 1530 1524 4 
210 9 24 1 LYDX 1526 1524 RGHT GOOD 068 68 1530 1524 0 
'"'-) 
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TABLE VII (Continued) 
OBS SUBJ BLK BOTL TRT RGHTI LEFT! LGINJ LEG HOUR TIME RGHT LEFT VOLDIF 
211 9 24 1 LYDX 1526 1524 RGHT SPRAIN 072 72 1532 1520 6 
212 9 24 1 LYDX 1526 1524 RGHT GOOD 072 72 1532 1520 -4 
213 9 24 1 LYDX 1526 1524 RGHT SPRAIN 084 84 1527 1526 1 
214 9 24 1 LYDX 1526 1524 RGHT GOOD 084 84 1527 1526 2 
215 9 24 1 LYDX 1526 1524 RGHT SPRAIN 168 168 1524 1520 -2 
216 9 24 1 LYDX 1526 1524 RGHT GOOD 168 168 1524 1520 -4 
217 10 24 2 DMSO 1699 1742 LEFT SPRAIN INJ 0 1686 1794 52 
218 10 24 2 DMSO 1699 1742 LEFT GOOD INJ 0 1686 1794 -13 
219 10 24 2 DMSO 1699 1742 LEFT SPRAIN 012 12 1717 1883 14 1 
220 10 24 2 DMSO 1699 1742 LEFT GOOD 012 12 1717 1883 18 
221 10 24 2 DMSO 1699 1742 LEFT SPRAIN 020 20 1722 1871 129 
222 10 24 2 DMSO 1699 1742 LEFT GOOD 020 20 1722 1871 23 
223 10 24 2 DMSO 1699 1742 LEFT SPRAIN 024 24 1738 1878 136 
224 10 24 2 DMSO 1699 1742 LEFT GOOD 024 24 1738 1878 39 
225 10 24 2 DMSO 1699 1742 LEFT SPRAIN 036 36 1706 1862 120 
226 10 24 2 DMSO 1699 1742 LEFT GOOD 036 36 1706 1862 7 
227 10 24 2 DMSO 1699 1742 LEFT SPRAIN 044 44 1714 1866 124 
228 10 24 2 DMSO 1699 1742 LEFT GOOD 044 44 1714 1866 15 
229 10 24 2 DMSO 1699 1742 LEFT SPRAIN 048 48 1692 1858 116 
230 10 24 2 DMSO 1699 1742 LEFT GOOD 048 48 1692 1858 -7 
231 10 24 2 DMSO 1699 1742 LEFT SPRAIN 060 60 1709 1829 87 
232 10 24 2 DMSO 1699 1742 LEFT GOOD 060 60 1709 1829 10 
233 10 24 2 DMSO 1699 1742 LEFT SPRAIN 068 68 1715 1812 70 
234 10 24 2 DMSO 1699 1742 LEFT GOOD 068 68 1715 1812 16 
235 10 24 2 DMSO 1699 1742 LEFT SPRAIN 072 72 1698 1792 50 
236 10 24 2 DMSO 1699 1742 LEFT GOOD 072 72 1698 1792 -1 
237 10 24 2 DMSO 1699 1742 LEFT SPRAIN 084 84 1690 1779 37 
238 10 24 2 DMSO 1699 1742 LEFT GOOD 084 84 1690 1779 -9 
239 10 24 2 DMSO 1699 1742 LEFT SPRAIN 168 168 1678 1751 9 
240 10 24 2 DMSO 1699 1742 LEFT GOOD 168 168 1678 1751 -21 
241 11 25 1 LYDX 1495 1495 RGHT SPRAIN INJ 0 1567 1482 72 
242 11 25 1 LYDX 1495 1495 RGHT GOOD INJ 0 1567 1482 -13 
243 1 1 25 1 LYDX 1495 1495 RGHT SPRAIN 012 12 1658 1545 163 
244 11 25 1 LYDX 1495 1495 RGHT GOOD 012 12 1658 1545 50 
245 1 1 25 1 LYDX 1495 1495 RGHT SPRAIN 020 20 1661 1556 166 
246 1 1 25 1 LYDX 1495 1495 RGHT GOOD 020 20 1661 1556 61 
247 11 25 1 LYDX 1495 1495 RGHT SPRAIN 024 24 1624 1532 129 
248 11 25 1 LYDX 1495 1495 RGHT GOOD 024 24 1624 1532 37 
249 11 25 1 LYDX 1495 1495 R~HT SPRAIN 036 36 1616 1519 121 
250 11 25 1 LYOX 1495 1495 RGHT GOOD 036 36 1616 1519 24 
251 11 25 1 LYDX 1495 1495 RGHT SPRAIN 044 44 1620 1519 125 
252 11 25 1 LYDX 1495 1495 RGHT GOOD 044 44 1620 1519 24 
'-.J 
(,)'1 
• 
TABLE VII (Continued) 
OBS SUBJ BLK BOTL TRT RGHTI LEFT I LGINu LEG HOUR TIME RGHT LEFT VOLDIF 
253 1 1 25 1 LYDX 1495 1495 RGHT SPRAIN 048 48 1612 1504 117 
254 11 25 1 LYDX 1495 1495 RGHT GOOD 048 48 1612 1504 9 
255 11 25 2 LYDX 1495 1495 RGHT SPRAIN 060 60 1525 1508 30 
256 11 25 2 LYDX 1495 1495 RGHT GOOD 060 60 1525 1508 13 
257 1 1 25 2 LYDX 1495 1495 RGHT SPRAIN 068 68 1532 1519 37 
258 1 1 25 2 LYDX 1495 1495 RGHT GOOD 068 68 1532 1519 24 
259 1 1 25 2 LYDX 1495 1495 RGHT SPRAIN 072 72 1512 1516 17 
260 11 25 2 LYDX 1495 1495 RGHT GOOD 072 72 1512 1516 21 
261 11 25 2 LYDX 1495 1495 RGHT SPRAIN 084 84 1506 1513 1 1 
262 11 25 2 LYDX 1495 1495 RGHT GOOD 084 84 1506 1513 18 
263 11 25 2 LYDX 1495 1495 RGHT SPRAIN 168 168 1508 1502 13 
264 1 1 25 2 LYDX 1495 1495 RGHT GOOD 168 168 1508 1502 7 
265 12 25 2 DMSO 1600 1562 LEFT SPRAIN INJ 0 1589 1674 112 
266 12 25 2 DMSO 1600 1562 LEFT GOOD INu 0 1589 1674 - 11 
267 12 25 2 DMSO 1600 1562 LEFT SPRAIN 012 12 1668 1706 144 
268 12 25 2 DMSO 1600 1562 LEFT GOOD 012 12 1668 1706 68 
269 12 25 2 DMSO 1600 1562 LEFT SPRAIN 020 20 1665 1707 145 
270 12 25 2 DMSO 1600 1562 LEFT GOOD 020 20 1665 1707 65 
271 12 25 2 DMSO 1600 1562 LEFT SPRAIN 024 24 1659 1681 119 
272 12 25 2 DMSO 1600 1562 LEFT GOOD 024 24 1659 1681 59 
273 12 25 2 DMSO 1600 1562 LEFT SPRAIN 036 36 1666 1 7 1 1 149 
274 12 25 2 DMSO 1600 1562 LEFT GOOD 036 36 166.6 17 11 66 
275 12 25 2 DMSO 1600 1562 LEFT SPRAIN 044 44 1681 1714 152 
276 12 25 2 DMSO 1600 1562 LEFT GOOD 044 44 1681 1714 81 
277 12 25 2 DMSO 1600 1562 LEFT SPRAIN 048 48 1653 1695 133 
278 12 25 2 DMSO 1600 1562 LEFT GOOD 048 48 1653 1695 53 
279 12 25 2 DMSO 1600 1562 LEFT SPRAIN 060 60 1642 1714 152 
280 12 25 2 DMSO 1600 1562 LEFT GOOD 060 60 1642 1714 42 
281 12 25 2 DMSO 1600 1562 LEFT SPRAIN 068 68 1658 1706 144 
282 12 25 2 DMSO 1600 1562 LEFT GOOD 068 68 1658 1706 58 
283 12 25 2 DMSO 1600 1562 LEFT SPRAIN 072 72 1643 1681 119 
284 12 25 2 DMSO 1600 1562 LEFT GOOD 072 72 1643 1681 43 
285 12 25 2 DMSO 1600 1562 LEFT SPRAIN 084 84 1630 1675 11 3 
286 12 25 2 DMSO 1600 1562 LEFT GOOD 084 84 1630 1675 30 
287 12 25 2 DMSO 1600 1562 LEFT SPRAIN 168 168 1612 1586 24 
288 12 25 2 DMSO 1600 1562 LEFT GOOD 168 168 1612 1586 12 
289 13 26 1 DMSO 1564 1576 RGHT SPRAIN INJ 0 1591 1562 27 
290 13 26 1 DMSO 1564 1576 RGHT GOOD INJ 0 1591 1562 -14 
291 13 26 1 OMSO 1564 1576 RGHT SPRAIN 012 12 1683 1581 119 
292 13 26 1 DMSO 1564 1576 RGHT GOOD 012 12 1683 1581 5 
293 13 26 1 DMSO 1564 1576 RGHT SPRAIN 020 20 1668 1584 104 
294 13 26 1 DMSO 1564 1576 RGHT GOOD 020 20 1668 1584 8 
'-.J 
Cl"' 
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TABLE VIII 
MEAN EDEMIC RESPONSES FOR EACH ANKLE 
AND TREATMENT COMBINATION 
OBS TRT LEG TlME TYPE FREQ M\/QLDIF 
-
0 336 40.8482 
2 (i 1 28 8.0714 
3 12 28 51.5000 
4 20 28 52.9643 
5 24 28 49.5357 
6 3.~ 28 50.2143 
7 44 28 48.4286 
8 qg 28 43.9286 
9 60 28 47.8214 
10 68 28 43.1429 
11 72 28 30.1071 
12 84 28 36.1429 
13 168 28 28.3214 
14 GOOD 2 168 18.9405 
1" 
.-J SPRAIN 2 168 62.7560 
!6 GOOD 0 3 14 -9.4286 
17 GOOD f "• .::: 3 14 23.5714 
18 GGOD 20 3 14 27.8571 
19 GOOD 24 3 14 25.2857 
20 GOOD 36 3 14 18.2143 
21 GOOD 44 < 14 23.6429 
~" GOOD 48 'J 14 17.0714 l..l.. 
'"' 
23 GOOD 60 3 14 25.7143 
24 GOOD '0 Ou 3 14 24.2143 
25 GOOD It 3 14 11.8571 
26 GOOD 84 3 j' .'! 18.500(! 
27 GOOD tf.8 3 14 20.7857 
28 SPRAIN 0 'J !4 25.5714 
'"' 
~0 
'-' SPRAIN 12 3 14 79.4286 
30 SPRAIN 20 3 14 78.07!4 
ji SPF:AIN 2~ 3 14 ~':l 7''~M !.,. • , tlJ I 
32. SP~:A IN ·"':/ JQ 3 14 82.2143 
""'!.-! 
,J,J SPRAIN 44 3 14 73.2143 
,jlf SPPAIN 48 'J !4 70.7857 
35 SF'F:AIN 60 3 !4 69. 9286 
36 SPRAIN ~·- ' 14 62.0714 
j.! SP~:A IN "72 ,, !!t 48.3571 
-.:·" SPPP.IN :34 3 14 53.7857 
28 SFEA I~\! 1.~;8 
" 
14 35.8571 
,',,·; Jl4SD 
" ltid 53.1607 , .... 
~ 1 LYDX 168 , ..... r:;.-. ........ ctL...:.::.J/ 
..; . : Di~SO 0 5 14 12.2143 
43 D\1SQ l::" 5 j' .'I 55.2857 
4 .:~ DMSO 20 5 14 56.5000 
45 D~1SO 24 ;} . 'l't 60.5000 
46 Dr~ so 36 5 j' .'t 71.0000 
47 Dl~SO 44 5 ~ ~ 64.2857 
48 ~.u,-;,-, 4B 14 62.0714 JC~JU ::: 
49 Dr! SO 6(i 5 14 74.2857 
TABLE VIII (Continued) 
GBS TRT LEG TIME 
50 DfiSO 68 
5! DNSO 72 
52 Oi'iSC 34 
53 DNSG 168 
54 LYDX (i 
55 LYDX 12 
56 L YD X 20 
57 LYDX c'l 
58 LYDX 36 
59 LYDX 44 
60 LYDX 48 
61 LYDJ. 60 
to: LYDX 68 
63 LYDX 72 
64 LYD~: 84 
65 LYDX 168 
66 DMSO SOQD 
~! OMSO SPRAIN 
68 LYDX GOOD 
69 LYDX SPRAIN 
70 DMSO GOOD 
? i DMSG GOOD 
72 OMSG GGOD. 
7~ DMSO GOOD 
75 DMSO 80GD 
76 DMSO GOOD 
77 DMSO GDGD 
78 DMSO GOOD 
79 DMSO GOOD 
80 DMSO ennn 
81 DMSD GOOD 
82 ~"~" SPRAIN 
83 DMSD SPRAIN 
84 DMSO SPRAIN 
85 DMSO SPRAIN 
~~ DMSO SPRAIN 
27 JMSC SPRAIN 
29 
9(1 
91 
92 
95 
'"'' .., .•. 
DMSC 
DMSO 
Dt~SO 
DMSO 
LYDX 
LYDX 
SPRAIN 
SPRP:l N 
SP~:f\!N 
SPRAlN 
SF'RA IN 
GOOD 
GOOD 
GOQD 
12 
24 
36 
6C 
68 
72 
84 
t 6~~ 
; •J 
.i.6-
24 
44 
48 
6C 
/C 
84 
168 
1 ~ 
•'-
20 
TYPE 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
7 
n' 
! 
7 
7 
7 
7 
? 
? 
7 
7 
7 
7 
? 
7 
7 
? 
_FREQ 
14 
14 
14 
14 
14 
14 
14 
14 
14 
14 
i4 
14 
14 
14 
14 
fll, 
J' 
84 
84 
84 
84 
7 
7 
7 
? 
7 
7 
7 
7 
7 
? 
7 
7 
7 
~­
; 
7 
7 
7 
7 
7 
7 
7 
7 
7 
HVOLDIF 
60.2143 
50.5000 
53.8571 
17.2143 
3 '9286 
47.7143 
49.429 
38.571 
29.429 
32.571 
25.786 
2!. 357 
26.071 
9.714 
18.429 
39.429 
19 '060 
87.262 
18,821 
38.250 
-12.571 
1':i 71' 
• u" • '! 
20.00(1 
26.571 
28.857 
' 26.857 
25.714 
37.?!4 
25.143 
!9.571 
!9.000 
-1.857 
37.000 
'16.857 
93.000 
94,429 
113' 143 
101.714 
98.429 
110.857 
95,286 
81.429 
88.714 
36.286 
-6.286 
33.429 
35.714 
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TABLE VIII (Continued) 
OBS FT LEG TIME TYPE FREQ MVOLDIF 
- -
97 LYDY. GOOD 24 7 7 24.000 
98 LYDX GOOD 36 7 7 7.571 
99 LYDX GOOD 44 7 7 20.429 
100 L!'OY. GOOD • Q qv 7 7 8.429 
!':;t LYDX GOOD 6(! 7 7 13.714 
102 LYOX GOOD 68 7 7 23.286 
~!)3 LYD:•: GOO.D 72 7 7 4.143 
!04 LYDX GOOD 84 7 7 18.000 
lOS LYDX GOOD 168 7 I 43.429 
!06 LY!H SPRA!tl 0 7 7 14 .143 
107 LYDX SPRAIN 12 7 7 62.000 
108 LYDX SPRAIN 20 7 7 63. !43 
!09 LYDX SPRAIN 24 7 7 53 .143 
l!iJ LYDX SPRAIN 36 7 '1 51.286 I 
111 LYDX SPRAIN 44 7 7 44.7143 
1! 2 LYDY. SPRAIN 48 7 7 43.1429 
113 LYDX SPRAIN 60 7 7 29.000(! 
1 t. ,q LYDY. SPP.AH! 68 7 7 28.857! 
pc 
,J LYDX SPRAW 72 ') 7 !5.285? 
!!6 LYDX SPRAIN 84 7 7 !8.857! 
1 ,., 
.11 LYDX £PRA!N U:3 7 7 35.4286 
MVOLUME 
1530 + 
1525 + 
1520 + 
1515 + 
1510 + 
1505 + 
1500 + 
I 
R 
L~ 
_.,. 
-
"' 
/ 
R 
L--
..,~ 
R-----------
R R 
- __ L ..... -. 
-L--- - -- ---- L 
--+-------------------------+-------------------------+-------------------------+-------------------------+-
1 2 3 4 5 
DAYS 
- R = Right 
- - L = Left 
Figure 7. Reliability Measurements of Ankles Over Time OJ 
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